難治性肝疾患の診療を極める

出版社： 文光堂
著者：
発行日： 2014-05-18
分野： 臨床医学：内科  >  肝/胆/膵
ISBN： 9784830618932
電子書籍版： 2014-05-18 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

11,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

11,000 円(税込)

購入する

商品紹介

難治性肝疾患の診療に役立つ基礎研究分野から臨床エビデンスに至る最先端の知見を網羅したテキスト．

目次

  • 難治性肝疾患の診療を極める

    ―目次―

    自己免疫性肝疾患編
    ?．基本編 〜自己免疫性肝疾患を診る前の基礎知識〜
    　１．肝と免疫システム
    　　A．自然免疫と獲得免疫
    　　B．肝構成細胞と免疫
    　２．自己免疫性肝疾患と自己抗体
    　３．自己免疫性肝疾患の発症機序
    　　A．AIHの発症機序
    　　B．PBCの発症機序
    　　C．PSCの発症機序
    　４．自己免疫性肝疾患の疫学
    　　A．AIHの疫学
    　　B．PBCの疫学
    　　C．PSCの疫学
    　５．自己免疫性肝疾患と原発性肝癌
    II．診断編
    　１．自己免疫性肝疾患の病理診断
    　２．自己免疫性肝疾患の診断
    　　A．AIHの診断
    　　B．PBCの診断
    　　C．PSCの診断
    　３．自己免疫性肝疾患非定型例の診断
    　４．小児のAIHとPSCの診断
    　Debate　IgG4関連AIHは存在するか
    　Lecture 核抗体陽性NASHとAIHとの鑑別
    　LectureIgG4関連硬化性胆管炎とPSC鑑別のポイント
    III．治療編
    　１．自己免疫性肝疾患の薬物療法
    　　A．AIHの治療
    　　B．PBCの治療
    　　C．PSCの治療
    　２．自己免疫性肝疾患に対する肝移植の現状
    　３．小児AIHとPSCの治療
    　Debate AIHはウルソデオキシコール酸単独治療で
    　　　　　コントロール可能か
    　Lecture ステロイド抵抗AIH例の対応について
    　Lecture AIH様病態を伴ったPBCの治療について
    IV．自己免疫性肝疾患を理解するための基礎研究
    　１．自己免疫性肝炎の動物モデル
    　２．自己免疫性肝疾患と遺伝子解析
    　３．自己免疫性肝炎とケモカイン・サイトカイン
    　４．AIHの新規自己抗体

    薬物性肝障害編
    ?．基本編 〜薬物性肝障害を診る前の基礎知識〜
    　１．薬物性肝障害の実態と疫学
    　２．薬物性肝障害の発生機序
    　Lecture 健康食品による肝障害
    　Lecture 薬物性肝内胆管消失症候群
    II．診断編
    　１．薬物性肝障害の診断
    　２．薬物性肝障害の病理
    III．治療編
    　１．薬物性肝障害の治療
    IV．薬物性肝障害を理解するための基礎研究
    　１．薬物性肝障害の危険因子
    　２．薬物起因性自己免疫性肝炎

    急性肝不全編
    ?．基本編 〜急性肝不全を診る前の基礎知識〜
    　１．急性肝不全と類縁疾患の概念
    　２．わが国における劇症肝炎・LOHFの実態（2009年以前）
    　３．わが国における急性肝不全の実態（2011年以降）
    　４．de novo B型肝炎の病態と対策
    II．診断編
    　１．急性肝不全の成因の診断
    　２．急性肝不全の劇症化予知
    　３．劇症肝炎・LOHFの予後予測および肝移植ガイドライン2008
    III．治療編
    　１．急性肝不全の治療ストラテジー
    　２．急性肝不全の人工肝補助療法
    　３．急性肝不全に対する肝移植
    　Debate on-line HDFは急性肝不全の標準的治療法となり得るか？
    IV．急性肝不全を理解するための基礎研究
    　１．劇症肝炎の発症機序　?アポトーシス・細胞死
    　２．劇症肝炎の発症機序　?微小循環障害
    　３．劇症肝炎の発症機序　?再生不全
    　４．急性肝不全に対する肝再生医療：HGFによる肝再生医療
    　５．急性肝不全に対する骨髄細胞を用いた肝再生医療の現状
    　Frontier 予後予測のデータマイニング

    その他の肝疾患編
    肝内結石症
    ?．基本編 〜肝内結石症を診る前の基礎知識〜
    　１．肝内結石症の定義と病型
    　２．肝内結石症の成因と病態
    　３．肝内結石症の疫学
    II．診断編
    　１．肝内結石症の診断
    　２．肝内結石症からの発癌
    III．治療編
    　１．肝内結石症の内科的治療
    　２．肝内結石症の外科的治療
    IV．肝内結石症を理解するための基礎研究
    　１．胆管癌の新規バイオマーカー
    　２．胆汁の遺伝子発現解析の試み

    門脈血行異常症
    ?．基本編 〜門脈血行異常症を診る前の基礎知識〜
    　１．特発性門脈圧亢進症
    　２．肝外門脈閉塞症とBudd-Chiari症候群
    　３．門脈血栓症
    　４．肝細静脈閉塞症
    II．診断編
    　１．門脈圧亢進症の画像診断
    III．治療編
    　１．門脈圧亢進症に対する内科的治療（IVR治療）
    　２．門脈圧亢進症に対する腹腔鏡下脾摘術と
    　　　　胃上部血行遮断兼脾摘術（Hassab術）
    IV．門脈血行異常症を理解するための基礎研究
    　１．門脈圧亢進症とサイトカイン

    金属代謝異常による肝疾患
    　１．ヘモクロマトーシス
    　２．ウィルソン病

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[ 自己免疫性肝疾患編 ]

P.7 掲載の参考文献
1) Akira S, Uematsu S, Takeuchi O : Pathogen recognition and innate immunity. Cell 124 ; 783-801, 2006
PubMed
2) Lee SH, Miyagi T, Biron CA : Keeping NK cells in highly regulated antiviral warfare. Trends Immunol 28 ; 252-259, 2007
PubMed
3) Crispe IN : The liver as a lymphoid organ. Annu Rev Immunol 27 ; 147-163, 2009
PubMed
4) Gao B, Jeong WI, Tian Z : Liver : An organ with predominant innate immunity. Hepatology 47 ; 729-736, 2008
PubMed
5) Doherty DG, O'Farrelly C : Innate and adaptive lymphoid cells in the human liver. Immunol Rev 174 ; 5-20, 2000
PubMed
6) Mehal WZ, Azzaroli F, Crispe IN : Immunology of the healthy liver : old questions and new insights. Gastroenterology 120 ; 250-260, 2001
PubMed
7) Tian Z, Chen Y, Gao B : Natural killer cells in liver disease. Hepatology 57 ; 1654-1662, 2013
 
8) Exley MA, Koziel MJ : To be or not to be NKT : natural killer T cells in the liver. Hepatology 40 ; 1033-1040, 2004
 
9) Crispe IN : Hepatic T cells and liver tolerance. Nat Rev Immunol 3 ; 51-62, 2003
PubMed
P.11 掲載の参考文献
1) Mehal WZ, Azzaroli F, Crispe IN : Immunology of the healthy liver : old questions and new insights. Gastroenterology 120 ; 250-260, 2001
PubMed
2) Stauffer JK, Scarzello AJ, Jiang Q, et al. : Chronic inflammation, immune escape, and oncogenesis in the liver : a unique neighborhood for novel intersections. Hepatology 56 ; 1567-1574, 2012
PubMed
3) Gershwin ME, Vierling JM, Manns MP : Liver immunology : principles and practice, Humana Press, 2007, p 26, 27, 29, 66, 67, 315
 
4) Knolle PA, Gerken G : Local control of the immune response in the liver. Immunol Rev 174 ; 21-34, 2000
PubMed
5) Bogdanos DP, Gao B, Gershwin ME : Liver immunology. Comp Physiol 3 ; 567-598, 2013
 
6) Parker GA, Picut CA : Immune functioning in non lymphoid organs : the liver. Toxicol Pathol 40 ; 237-247, 2012
PubMed
7) Crispe IN : The liver as a lymphoid organ. Ann Rev Immunol 27 ; 147-163, 2009
 
8) Crispe IN : Liver antigen-presenting cells. J Hepatol 54 ; 357-365, 2011
PubMed
9) Krueger PD, Lassen MG, Qiao H, et al. : Regulation of NK cell repertoire and function in the liver. Crit Rev Immunol 31 ; 43-52, 2011
PubMed
10) Swain MG : Natural killer T cells within the liver : conductors of the hepatic immune orchestra. Dig Dis 28 ; 7-13, 2010
PubMed
P.16 掲載の参考文献
1) 三森経世 : 概論 : 自己抗体測定法と自己抗原分析の進歩. 日本臨牀 68 (S6) ; 479-484, 2010
 
2) Krawitt EL : Discrimination of autoimmune hepatitis : autoantibody typing and beyond. J Gastroenterol 46 (S1) ; 39-41, 2011
 
3) Liberal R, Grant CR, Mieli-Vergani G, et al. : Autoimmune hepatitis : a comprehensive review. J Autoimmun 41 ; 126-139, 2013
PubMed
4) Johnson GD, Holborow EJ, Glynn LE : Antibody to smooth muscle in patients with liver disease. Lancet 2 ; 878-879, 1965
PubMed
5) 北澤絵里子, 宮川浩 : 自己免疫性肝炎II型の現況. Modern Physician 23 ; 539-541, 2003
 
6) 大平弘正, 物江恭子, 菅野有紀子 他 : 自己免疫性胆管疾患での自己抗体とその病的意義. 肝胆膵 62 ; 629-637, 2011
Medical*Online
7) Gershwin ME, Mackay IR, Sturgess A, et al. : Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 138 ; 3525-3531, 1987
PubMed
8) 中村稔, 相葉佳洋, 小森敦正他 : PBCの予後予測 : 自己抗体を基盤に. 肝胆膵 62 ; 707-714, 2011
Medical*Online
9) Nakamura M, Kondo H, Mori T, et al. : Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45 ; 118-127, 2007
PubMed
10) Karrar A, Broome U, Sodergren T, et al. : Biliary epithelial cell antibodies link adaptive and innate immune response in primary sclerosing cholangitis. Gastroenterology 132 ; 1504-1514, 2007
PubMed
P.20 掲載の参考文献
1) Seki T, Ota M, Furuta S, et al. : HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 103 ; 1041-1047, 1992
PubMed
2) Vento S, Cainelli F : Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev 3 ; 61-69, 2004
 
3) Chen L, Zhang Z, Chen W, et al. : B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol 178 ; 6634-6641, 2007
 
4) Longhi MS, Ma Y, Bogdanos DP, et al. : Impairment of CD4 (+) CD25 (+) regulatory T-cells in autoimmune liver disease. J Hepatol 41 ; 31-37, 2004
PubMed
5) Peiseler M, Sebode M, Franke B, et al. : FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 57 ; 125-132, 2012
 
6) Tamaki S, Homma S, Enomoto Y, et al. : Autoimmune hepatic inflammation by vaccination of mice with dendriticcells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12. Clin Immunol 117 ; 280-293, 2005
 
7) Saeki C, Nakano M, Takahashi H, et al. : Accumulation of functional regulatory T cells in actively inflamed liver in mouse dendritic cell-based autoimmune hepatic inflammation. Clin Immunol 135 ; 156-166, 2010
PubMed
8) Zhao L, Tang Y, You Z, et al. : Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin- 6 expression. PLoS One 6 ; e18909, 2011
 
9) Rong G, Zhou Y, Xiong Y, et al. : Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis : the serum cytokine profile and peripheral cell population. Clin Exp Immunol 156 ; 217-225, 2009
 
10) Oikawa T, Takahashi H, Ishikawa T, et al. : Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int 57 ; 485-492, 2007
PubMed
11) Kassel R, Cruise MW, Iezzoni JC, et al. : Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology 50 ; 1625-1637, 2009
PubMed
P.25 掲載の参考文献
1) Nakamura M, Nishida N, Kawashima M, et al. : Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 91 ; 721-728, 2012
PubMed
2) Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. : Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 42 ; 386-392, 2005
PubMed
3) Shimoda S, Nakamura M, Ishibashi H, et al. : HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis : evidence of molecular mimicry in human autoimmune diseases. J Exp Med 181 ; 1835-1845, 1995
PubMed
4) Kita H, Lian ZX, Van de Water J, et al. : Identification of HLA-A2-restricted CD8 (+) cytotoxic T cell responses in primary biliary cirrhosis : T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 195 ; 113-123, 2002
PubMed
5) Shimoda S, Nakamura M, Shigematsu H, et al. : Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology 31 ; 1212-1216, 2000
PubMed
6) Tanimoto H, Shimoda S, Nakamura M, et al. : Promiscuous T cells selected by Escherichia coli : OGDC-E2 in primary biliary cirrhosis. J Autoimmun 20 ; 255-263, 2003
PubMed
7) Shimoda S, Nakamura M, Ishibashi H, et al. : Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology 124 ; 1915-1925, 2003
PubMed
8) Shimoda S, Harada K, Niiro H, et al. : Biliary epithelial cells and primary biliary cirrhosis : the role of liver-infiltrating mononuclear cells. Hepatology 47 ; 958-965, 2008
PubMed
9) Shimoda S, Harada K, Niiro H, et al. : Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 53 ; 1270-1281, 2011
PubMed
10) Lleo A, Selmi C, Invernizzi P, et al. : Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology 49 ; 871-879, 2009
PubMed
P.29 掲載の参考文献
1) 平野賢二 : 原発性硬化性胆管炎 (PSC). 診断と治療 101 ; 779-784, 2013
Medical*Online
2) Takikawa H, et al. : Analysis of 388 cases of primary sclerosing cholangitis in Japan. Hepatol Res 29 ; 153-159, 2004
PubMed
3) Karrar A, et al. : Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 132 ; 1504-1514, 2007
PubMed
4) Neri TM, et al. : Novel association of HLA-haplotypes with PSC in a southern European population. Dig Liver Dis 35 ; 571-576, 2003
 
5) Jayant A : Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology 11 ; 898-907, 2013
 
6) 茶山一彰他 : 肝疾患の疾患関連遺伝子-GWASを含めた最近の知見から-. 日消誌 110 ; 1577-1580, 2013
Medical*Online
7) Fosby B, Karlsen TH, et al. : Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 18 ; 1-15, 2012
PubMed
8) Rudolph G, et al. : Influence of dominant bile duct stenosis and biliary infection on outcome in primary sclerosing cholangitis. J Hepatol 51 ; 149-155, 2009
PubMed
9) Aron JH, Bowlus CL : The immunobiology of primary sclerosing cholangitis. Semin Immunopathol 31 ; 383-397, 2009
PubMed
10) Hirschfield GM, Karlsen TH, et al. : Primary sclerosing cholangitis. Lancet 382 ; 1587-1599, 2013
PubMed
P.34 掲載の参考文献
1) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 (編) : 自己免疫性肝炎 (AIH) の診療ガイド, 文光堂, 2011
 
2) 恩地森一, 阿部雅則 : 自己免疫性肝炎診療・研究の現状と今後. 日本消化器病学会雑誌 108 ; 1823-1836, 2011
Medical*Online
3) Mackay IR, Weiden S, Hasker J : Autoimmune hepatitis. Ann N Y Acad Sci 124 ; 767-780, 1965
PubMed
4) Abe M, Mashiba T, Zeniya M, et al. : Present status of autoimmune hepatitis in Japan : a nationwide survey. J Gastroenterol 46 ; 1136-1145, 2011
PubMed
5) 大浦麻絵 : 全国疫学調査による難治性の肝疾患の日本の患者数推定. 肝胆膵 54 ; 425-430, 2007
Medical*Online
6) 戸田剛太郎, 渡辺文時, 銭谷幹男 : 自己免疫性肝炎発生の疫学. 日本内科学会雑誌 88 ; 572-577, 1999
 
7) Michitaka K, Nishiguchi S, Aoyagi Y, et al. : Etiology of liver cirrhosis in Japan : a nationwide survey. J Gastroenterol 45 ; 86-94, 2010
PubMed
8) 大平弘正, 青柳豊, 恩地森一 他 : 自己免疫性肝炎分科会分担研究報告書 病態解析ワーキンググループ. 厚生労働科学研究費補助金難治性疾患克服研究事業 難治性の肝・胆道疾患に関する調査研究 平成24年度総括・分担研究報告書, 2013, 13-14
 
P.39 掲載の参考文献
1) 廣原淳子, 仲野俊成, 關壽人他 : 原発性胆汁性肝硬変全国調査 (第33報) -第15回原発性胆汁性肝硬変全国調査結果-. 厚生労働科学研究費補助金難治性疾患克服研究事業 難治性の肝・胆道疾患に関する調査研究 平成24年度総括・分担研究報告書, 2013, 63-67
 
2) 厚生労働省特定疾患医療受給者証交付件数 : 財団法人難病医学研究財団難病情報センターホームページ (http://www.nanbyou.or.jp/top.html)
 
3) 井上恭一, 廣原淳子, 仲野俊成 : 原発性胆汁性肝硬変 1. 発生の疫学. 日内会誌 88 ; 597-602, 1999
 
4) Poupon R : Primary biliary cirrhosis : a 2010 update. J Hepatology 52 ; 745-758, 2010
 
5) 廣原淳子, 仲野俊成, 關壽人他 : 原発性胆汁性肝硬変全国調査 (第29報). 厚生労働科学研究費補助金難治性疾患克服研究事業 難治性の肝・胆道疾患に関する調査研究 平成20年度総括・分担研究報告書, 2009, 53-55
 
6) 廣原淳子, 仲野俊成, 關壽人他 : 原発性胆汁性肝硬変 (PBC) 全国調査にみる本邦PBCの病態と予後の変遷. 日消誌 110 ; 8-15, 2013
Medical*Online
7) Harada K, Hirohara J, Ueno Y, et al. : Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis : National data from Japan. Hepatology 57 ; 1942-1949, 2013
PubMed
8) 石橋大海, 中沼安二, 上野義之他 : 原発性胆汁性肝硬変 (PBC) の診療ガイドライン (2012年) : 肝臓 53 ; 633-686, 2012
 
9) Nakano T, Inoue K, Hirohara J, et al. : Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (aPBC). Hepatol Res 22 ; 250-260, 2002
PubMed
10) 廣原淳子, 仲野俊成, 關壽人他 : 原発性胆汁性肝硬変全国調査 (第31報) -全国調査にみる30年間の予後の変遷-. 厚生労働科学研究費補助金難治性疾患克服研究事業 難治性の肝・胆道疾患に関する調査研究平成22 年度総括・分担研究報告書, 2011, 59-62
 
P.44 掲載の参考文献
1) 岡崎和一, 川茂幸, 乾和郎他 : IgG4関連硬化性胆管炎臨床診断基準 2012. 胆道 26 ; 59-63, 2012
 
2) 田中篤, 田妻進, 岡崎和一他 : 硬化性胆管炎の全国調査. 胆道 27 ; 176-187, 2013
Medical*Online
3) Tanaka A, Takikawa H : Geoepidemiology of primary sclerosing cholangitis : A critical review. J Autoimmun 46 ; 35-40, 2013
PubMed
4) 滝川一 : PSCの全国疫学調査. 厚生労働科学研究補助金 難治性疾患克服研究事業報告書, 2008
 
5) Boonstra K, Weersma RK, van Erpecum KJ, et al. : Population-based epidemiology, malignancy risk and outcome of primary sclerosing cholangitis. Hepatology 58 ; 2045-2055, 2013
PubMed
6) Lindkvist B, Benito de Valle M, Gullberg B, et al. : Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 52 ; 571-577, 2010
 
7) Card TR, Solaymani-Dodaran M, West J : Incidence and mortality of primary sclerosing cholangitis in the UK : a population-based cohort study. J Hepatol 48 ; 939-944, 2008
 
8) Kaplan G, Laupland K, Butzner D, et al. : The burden of large and small duct primary sclerosing cholangitis in adults and children : a population-based analysis. Am J Gastroenterol 102 ; 1042-1049, 2007
PubMed
9) Hirschfield GM, Karlsen TH, Lindor KD, et al. : Primary sclerosing cholangitis. Lancet 382 ; 1587-1599, 2013
PubMed
10) Karlsen TH, Boberg KM : Update on primary sclerosing cholangitis. J Hepatol 59 : 571-582, 2013
PubMed
P.49 掲載の参考文献
1) Taura N, Fukushima N, Yastuhashi H, et al. : The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit 17 ; PH 7-11, 2011
 
2) Yeoman AD, Al-Chalabi T, Karani JB, et al. : Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis : Implications for follow-up and screening. Hepatology 48 ; 863-870, 2008
PubMed
3) Montano-Loza AJ, Carpenter HA, Czaja AJ, et al. : Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 103 ; 1944-1951, 2008
PubMed
4) Watanabe T, Soga K, Hirono H, et al. : Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol 15 ; 231-239, 2009
PubMed
5) Wong RJ, Gish R, Frederick T, et al. : Development of hepatocellular carcinoma in autoimmune hepatitis patients : a case series. Dig Dis Sci 56 ; 578-585, 2011
PubMed
6) Migita K, Watanabe Y, Jiuchi Y, et al. : Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int 32 ; 837-844, 2012
PubMed
7) Hino-Arinaga T, Ide T, Kuromatsu R, et al. : Autoimmune Hepatitis Study Group. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol 47 ; 569-576, 2012
 
8) Ohira H, Abe K, Takahashi A, et al. : Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. J Gastroenterol 48 ; 109-114, 2013
PubMed
9) Harada K, Hirohara J, Ueno Y, et al. : Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis : national data from Japan. Hepatology 57 ; 1942-1949, 2013
PubMed
10) Liang Y, Yang Z, Zhong R : Primary biliary cirrhosis and cancer risk : a systematic review and meta-analysis. Hepatology 56 ; 1409-1417, 2012
 
11) Tanaka A, Takikawa H : Geoepidemiology of primary sclerosing cholangitis : A critical review. J Autoimmun 46 ; 35-40, 2013
PubMed
12) Chapman MH, Webster GJ, Bannoo S, et al. : Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis : a 25-year single-centre experience. Eur J Gastroenterol Hepatol 24 ; 1051-1058, 2012
PubMed
13) Razumilava N, Gores GJ, Lindor KD : Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 54 ; 1842-1852, 2011
PubMed
P.57 掲載の参考文献
1) Hennes EM, Zeniya M, Czaja AJ, et al. : Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 ; 169-176, 2008
PubMed
2) Dienes HP : Viral and autoimmune hepatitis. Morphologic and pathogenetic aspects of cell damage in hepatitis with potential chronicity. Veroff Pathol 132 ; 1-107, 1989
PubMed
3) Onji M : Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res 41 ; 497, 2011
PubMed
4) Misdraji J, Thiim M, Graeme-Cook FM : Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 28 ; 471-478, 2004
PubMed
5) Isse K, Harada K, Sato Y, et al. : Characterization of biliary intra-epithelial lymphocytes at different anatomical levels of intrahepatic bile ducts under normal and pathological conditions : numbers of CD4+ CD28- intra-epithelial lymphocytes are increased in primary biliary cirrhosis. Pathol Int 56 ; 17-24, 2006
PubMed
6) Nakanuma Y, Ohta G : Histometric and serial section observations of the intrahepatic bile ducts in primary biliary cirrhosis. Gastroenterology 76 ; 1326-1332, 1979
PubMed
7) Harada K, Minato H, Hiramatsu K, et al. : Epithelioid cell granulomas in chronic hepatitis C : immunohistochemical character and histological marker of favourable response to interferon-alpha therapy. Histopathology 33 ; 216-221, 1998
PubMed
8) Harada K, Kono N, Tsuneyama K, et al. : Cell-kinetic study of proliferating bile ductules in various hepatobiliary diseases. Liver 18 ; 277-284, 1998
PubMed
9) Khan FM, Komarla AR, Mendoza PG, et al. : Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis : "minimal change PBC"? Hepatology 57 ; 700-707, 2013
PubMed
10) Aishima S, Kuroda Y, Nishihara Y, et al. : Characteristic differences according to the cirrhotic pattern of advanced primary biliary cirrhosis : Macronodular cirrhosis indicates slow progression. Hepatol Res 36 ; 188-194, 2006
 
11) Nakanuma Y, Zen Y, Harada K, et al. : Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens : Interobserver agreement. Pathol Int 60 ; 167-174, 2010
PubMed
12) 石橋大海, 中沼安二, 上野義之他 : 原発性胆汁性肝硬変 (PBC) の診療ガイドライン (2012年). 肝臓 53 ; 633-686, 2012
 
P.61 掲載の参考文献
1) Alvarez R, Berg PA, Bianchi FB, et al. : International Autoimmune Hepatitis Group Report : review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 ; 929-938, 1999
 
2) Abe M, Mashiba T, Zeniya M, et al. : Present status of autoimmune hepatitis in Japan : a nationalwide survey. J Gastroenterol 46 ; 1136-1141, 2011
 
3) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 (編) : 自己免疫性肝炎 (AIH) の診療ガイド, 文光堂, 2011
 
4) 恩地森一, 銭谷幹男, 山本和秀他 : 自己免疫性肝炎の診断指針・治療指針 (2013年). 肝臓 54 ; 723-725, 2013
 
5) Hennes EM, Zeniya M, Czaja AJ, et al. : Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 ; 169-176, 2008
PubMed
P.65 掲載の参考文献
1) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 (編) : 原発性胆汁性肝硬変 (PBC) の診療ガイド, 文光堂, 2010
 
2) 廣原淳子他 : 原発性胆汁性肝硬変 (PBC) 全国調査にみる本邦PBCの病態と予後の変遷. 日消誌 110 ; 8-15 : 2013
Medical*Online
3) Lindor KD, et al. : AASLD practice guidelines Primary Biliary cirrhosis. Hepatology 50 ; 291-308, 2009
 
4) Raoul P : primary biliary cirrhosis : A 2010 update. J of Hepatol 52 ; 745-758, 2010
 
5) Hirschfield GM, et al. : Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol 25 ; 701-712, 2011
PubMed
6) Zamanou A, et al. : Anti-smooth muscle antibodies (ASMAs) and anti-cytoskeleton antibodies (ACTAs) in liver diseases : a comparison of classical indirect immunofluorescence with ELISA. J Clin Lab Anal 16 ; 194-201, 2002
PubMed
7) Nakamura M, et al. : Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biriary cirrhosis. J Hepatol 42 ; 386-392, 2005
PubMed
8) Maeda T, et al. : lmmunogenetic studies of primary biliary cirrhosis. Autoimmune liver disease, 2 nd edition, Elsevier, 1998, pp 167-178
 
9) Chow IT, et al. : Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB1*08 : 01 and DRB1*11 : 01 Is predicted by their structural motifs and correlates with disease risk. J Immunol 190 ; 4516-4524, 2013
 
10) Ishibashi H, et al. : Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 50 ; 1-10, 2011
PubMed
11) Yan L, et al. : Primary Biliary Cirrhosis and cancer risk : a systematic review and meta-analysis Hepatology 56 ; 1409-1417, 2012
 
12) Nakamura M, et al. : Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45 ; 118-127, 2007
PubMed
P.69 掲載の参考文献
1) 田中篤, 田妻進, 岡崎和一他 : 硬化性胆管炎の全国調査. 胆道 27 ; 176-187, 2013
Medical*Online
2) Terjung B, Spengler U, Sauerbruch T, et al. : "Atypical pANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119 ; 310-322, 2000
PubMed
3) Nakazawa T, Ohara H, Sano H, et al. : Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas 32 ; 229, 2006
PubMed
4) Nakazawa T, Ohara H, Sano H, et al. : Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 60 ; 937-944, 2004
PubMed
5) 中沢貴宏, 大原弘隆, 城卓志 : IgG4関連硬化性胆管炎の診断と治療. 胆道 24 ; 569-578, 2010
Medical*Online
6) 岡崎和一, 川茂幸, 乾和郎他 : IgG4関連硬化性胆管炎臨床診断基準 2012. 胆道 26 ; 59-63, 2012
 
P.73 掲載の参考文献
1) Czaja AJ, Bayraktar Y : Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol 15 ; 2314-2328, 2009
PubMed
2) Toda G, Zeniya M, Watanabe F, et al. : Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol 26 ; 1207-1212, 1997
 
3) Abe M, Mashiba T, Zeniya M, et al. : Present status of autoimmune hepatitis in Japan : a nationwide survey. J Gastroenterol 46 ; 1136-1141, 2011
PubMed
4) Miyake Y, Iwasaki Y, Kobashi H, et al. : Clinical features of antinuclear antibodies-negative type 1 autoimmune hepatitis. Hepatol Res 39 ; 241-246, 2009
PubMed
5) Onji M, autoimmune hepatitis study group : Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res 41 ; 497, 2011
 
6) Miyake Y, Iwasaki Y, Kobashi H, et al. : Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis 42 ; 51-54, 2010
PubMed
7) 坪内博仁 : 劇症肝炎及び遅発性肝不全の全国集計 (2009年). 厚生労働省難治性疾患克服研究事業 「難治性の肝・胆道疾患に関する調査研究班」平成22年度総括・分担研究報告書, 2011, 96-113
 
8) 横須賀收 : 自己免疫性急性肝不全の診断に関する検討. 厚生労働省難治性疾患克服研究事業 「難治性の肝・胆道疾患に関する調査研究班」平成21年度総括・分担研究報告書, 2010, 124-125
 
9) Czaja AJ : Drug-Induced Autoimmune-Like Hepatitis. Dig Dis Sci 56 ; 958-976, 2011
PubMed
10) Liu B, Shi XH, Zhang FC, et al. : Antimitochondrial antibody-negative primary biliary cirrhosis : a subset of primary biliary cirrhosis. Liver Int 28 ; 233-239, 2008
PubMed
11) 滝川一 : AIH-PBCオーバーラップ症候群の実態調査. 厚生労働省難治性疾患克服研究事業 「難治性の肝・胆道疾患に関する調査研究班」平成21年度総括・分担研究報告書, 2010, 49-52
 
12) Neuhauser M, bjornsson E, Treeprasertsuk S, et al. : Autoimmune hepatitis-PBC overlap syndrome : a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 105 ; 345-353, 2010
PubMed
13) Chazouilleres O, Wendum D, Serfaty L, et al. : Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome : clinical features and response to therapy. Hepatology 28 ; 296-301, 1998
PubMed
14) Boberg KM, Chapman RW, Hirschfield GM, et al. : Overlap syndromes : The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 54 ; 374-385, 2011
PubMed
P.77 掲載の参考文献
1) Gregorio GV, Portmann B, Reid F, et al. : Autoimmune hepatitis in childhood : a 20-year experience. Hepatology 25 ; 541-547, 1997
PubMed
2) Fujisawa T, Sogo T, Komatsu H, et al. : Autoimmune hepatitis in childhood. Hepatol Res 37 ; S 496-500, 2007
 
3) 十河剛, 橋本卓史, 小松陽樹他 : 自己免疫性肝炎. 小児内科 40 増刊号 ; 594-599, 2008
 
4) Alvarez F, Berg PA, Bianchi FB, et al. : International autoimmue hepatitis group report : review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 ; 929-938, 1999
 
5) Mieli-Vergani G, Heller S, Jara P, et al. : Autoimmune hepatitis. JPGN 49 ; 158-164, 2009
PubMed
6) Manns MP, Vogel A : Autoimmune hepatitis, from mechanism to therapy. Hepatology 43 ; S 132-S 144, 2006
 
7) 十河剛, 藤澤知雄 : 小児期の自己免疫性肝炎における肝病理学的検討. 日本小児科会誌 110 ; 1558-1564, 2006
 
8) Deneau M, Jensen MK, Holmen J, et al. : Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children : epidemiology and natural history. Hepatology 58 ; 1392-1400, 2013
PubMed
9) 十河剛, 角田知之, 川本愛里他 : 小児期原発性硬化性胆管炎発症早期のERCP所見. 小児内科 44 ; 250-253, 2012
 
10) Mieli-Vergani G, Vergani D : Autoimmune paediatric liver disease. World J Gastroenterol 14 ; 3360-3367, 2008
PubMed
11) Kerkar N, Hadzic N, Daivis ET, et al. : de novo autoimmune hepatitis after transplantation. Lancet 351 ; 409-413, 1998
 
P.80 掲載の参考文献
1) Stone JH, Zen Y, Deshpande V : IgG4-related disease. N Engl J Med 366 ; 539-551, 2012
PubMed
2) Umemura T, Zen Y, Hamano H, et al. : Immunoglobin G4-hepatopathy : association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 46 ; 463-471, 2007
PubMed
3) Stone JH, Khosroshahi A, Deshpande V, et al. : Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 64 ; 3061-3067, 2012
PubMed
4) Nishino T, Oyama H, Hashimoto E, et al. : Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol 42 ; 550-559, 2007
PubMed
5) Naitoh I, Zen Y, Nakazawa T, et al. : Small bile duct involvement in IgG4-related sclerosing cholangitis : liver biopsy and cholangiography correlation. J Gastroenterol 46 ; 269-276, 2011
PubMed
6) Alvarez F, Berg PA, Bianchi FB, et al. : International Autoimmune Hepatitis Group Report : review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 ; 929-938, 1999
PubMed
7) Umemura T, Zen Y, Hamano H, et al. : IgG4 associated autoimmune hepatitis : a differential diagnosis for classical autoimmune hepatitis. Gut 56 ; 1471-1472, 2007
PubMed
8) Umemura T, Zen Y, Nakanuma Y, et al. : Another cause of autoimmune hepatitis. Hepatology 52 ; 389-390, 2010
PubMed
9) Umemura T, Zen Y, Hamano H, et al. : Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol 46 Suppl 1 ; 48-55, 2011
 
P.83 掲載の参考文献
1) Targher G, Bertolini L, RodellaS, et al. : Association between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol 64 ; 337-341, 2006
 
2) Chalasani N, Younossi F, Lavine FJ, et al. : The diagnosis and management of non-alcoholic fatty liver disease : practice guideline by american association for the study of liver disease, American collage of gastroenterology, and the American gastroenterological association. Hepatology 55 ; 2005-2023, 2012
 
3) Yatsuji S, Hashimoto E, Kaneda H, et al. : Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease : is the international autoimmune hepatitis group scoring system useful? J Gastroenterol 40 ; 1130-1138, 2005
PubMed
4) Loria P, Lonardo A, Leonardi F, et al. : Non-organ-specific autoantibodies in nonalcoholic fatty liver disease : Prevalence and correlates. Dig Dis Sci 48 ; 2173-2181, 2003
PubMed
5) Adams LA, Lindor KD, Angulo P, et al. : The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 1316-1320, 2004
PubMed
6) Niwa H, Sasaki M, Haratake J, et al. : Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol Res 37 ; 923-931, 2007
PubMed
7) Vuppalanchi R, Gould RJ, Wilson LA, et al. : Clinical significance of serum autoantibodies in patients with NAFLD : results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2011 [Epub ahead of print]
 
8) Fukuda S, Komori A, Itho M, et al. : Histological remission during corticosteroid therapy of overlapping nonalcoholic steatohepatitis and autoimmune hepatitis : Case report and literature review. Case Rep Gastroenterol 5 ; 553-557, 2011
 
P.88 掲載の参考文献
1) 厚生労働省IgG 4 関連全身硬化性疾患の診断法の確立と治療方法の開発に関する研究班, 厚生労働省難治性の肝胆道疾患に関する調査研究班, 日本胆道学会 : IgG4関連硬化性胆管炎臨床診断基準 2012. 胆道 26 ; 59-63, 2012
Medical*Online
2) Ohara H, Okazaki K, Tsubouchi H, et al. : Clinical diagnostic criteria of IgG 4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 19 ; 536-542, 2012
 
3) Nakazawa T, Ohara H, Sano H, et al. : Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 60 ; 937-944, 2004
PubMed
4) Nakazawa T, Ohara H, Sano H, et al. : Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas 32 ; 229, 2006
PubMed
P.92 掲載の参考文献
1) Yoshizawa K, Matsumoto A, Ichijo T, et al. : Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 56 ; 668-676, 2012
PubMed
2) Czaja AJ : Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 29 ; 816-823, 2009
PubMed
3) Miyake Y, Iwasaki Y, Terada R, et al. : Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 43 ; 951-957, 2005
PubMed
4) Miyake Y, Iwasaki Y, Terada R, et al. : Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 24 ; 1197-1205, 2006
PubMed
5) Takenami T, Sakaguchi K, Nishimura M, et al. : Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1. Acta Med Okayama 55 ; 341-347, 2001
PubMed
6) Johnson PJ, McFarlane IG, Williams R : Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333 ; 958-963, 1995
PubMed
7) Manns MP, Woynarowski M, Kreisel W, et al. : European AIH-BUC-Study Group : Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139 ; 1198-1206, 2010
 
8) Zachou K, Gatselis N, Papadamou G, et al. : Mycophenolate for the treatment of autoimmune hepatitis : prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 55 ; 636-646, 2011
 
9) Hlivko JT, Shiffman ML, Stravitz RT, et al. : A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 6 ; 1036-1040, 2008
PubMed
10) Yamamoto K, Miyake Y, Ohira H, et al. : Intractable Liver and Biliary Diseases Study Group of Japan : Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res 43 ; 630-638, 2013
 
P.96 掲載の参考文献
1) 厚生労働省「難治性の肝疾患に関する研究」班 : 原発性胆汁性肝硬変全国調査. 平成14年度総括・分担研究報告書, 2003, 55-59
 
2) Iwasaki S, Ohira H, Nishiguchi S, et al. : The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis : A prospective, multicenter study. Hepatol Res 38 ; 557-564, 2008
PubMed
3) 石橋大海, 中沼安二, 上野義之他 : 厚生労働省難治性疾患克服研究事業「難治性の肝・胆道疾患に関する調査研究」班 原発性胆汁性肝硬変 (PBC) の診療ガイドライン (2012年). 肝臓 53 ; 633-686, 2012
 
4) Combes B, Carithers RL Jr, Maddrey WC, et al. : Biliary Bile Acids in Primary Biliary Cirrhosis : Effect of Ursodeoxycholic Acid. Hepatology 29 ; 1649-1654, 1999
PubMed
5) Shi J, Wu C, Lin Y, et al. : Long-term effects of middose ursodeoxycholic acid in primary biliary cirrhosis : a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 ; 1529-1538, 2006
 
P.100 掲載の参考文献
1) 滝川一 : 硬化性胆管炎の全国調査. 難治性の肝 胆道疾患に関する調査研究 平成24年度版, 2013, 75-77
 
2) Lindor KD : Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 36 ; 691-695, 1997
 
3) Olsson R, Boberg KM, de Muckadell OS, et al. : High-dose ursodeoxycholic acid in primary sclerosing cholangitis : a 5-year multicenter, randomized, controlled study. Gastroenterology 129 ; 1464-1472, 2005
PubMed
4) Chapman R, Fevery J, Kalloo A, et al. : Diagnosis and management of primary sclerosing cholangitis. Hepatology 51 ; 660-678, 2010
PubMed
5) Sasatomi K, Noguchi K, Sakisaka S, et al. : Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 29 ; 409-416, 1998
PubMed
6) Karlsen TH, Boberg KM : Update on primary sclerosing cholangitis. J Hepatol 59 ; 571-582, 2013
PubMed
7) Fickert P, Wagner M, Marschall HU, et al. : 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr 2 (Abcb 4) knockout mice. Gastroenterology 130 ; 465-481, 2006
 
8) Brandsaeter B, Isoniemi H, Broome U, et al. : Liver transplantation for primary sclerosing cholangitis ; predictors and consequences of hepatobiliary malignancy. J Hepatol 40 ; 815-822, 2004
PubMed
9) Stiehl A, Rudolph G, Sauer P, et al. : Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 26 ; 560-566, 1997
PubMed
10) Kim WR, Therneau TM, Wiesner RH, et al. : A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75 ; 688-694, 2000
PubMed
11) Graziadei IW : Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 8 ; 575-581, 2002
PubMed
P.105 掲載の参考文献
1) 日本肝移植研究会 : 肝移植症例登録報告. 移植 46 ; 524-536, 2011
Medical*Online
2) Trotter JF : Is disease recurrence still relevant to graft survival? Liver Transplant 19 ; S 49-S 55, 2013
 
3) Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2011 Data Report. Am J Transplant 13 Suppl 1 ; 1-234, 2013
 
4) Watt KD, Pedersen RA, Kremers WK, et al. : Evolution of causes and risk factors for mortality post-liver transplant results of the NIDDK long-term followup study. AM J Transplant 10 ; 1420-1427, 2010
PubMed
5) Campsen J, Zimmerman M, Trotter J, et al. : Liver transplantation for primary biliary cirrhosis : result of aggressive corticosteroid withdrawal. Transplant Proc 41 ; 1707-1712, 2009
PubMed
6) Gautam M, Cheruvattath R, Balan V : Recurrence of autoimmune liver disease after liver transplantation : a systematic review. Liver Transpl 12 ; 1813-1824, 2006
PubMed
7) Egawa H, Ueda Y, Ichida T, et al. : Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Amer J Transplant 11 ; 518-527, 2011
 
8) Campsen J, Zimmerman MA, Trotter JF, et al. : Clinically recurrent primary sclerosing cholangitis following liver transplantation : a time course. Liver Transpl 14 ; 181-185, 2008
PubMed
P.110 掲載の参考文献
1) Gregorio GV, Portmann B, Reid F, et al. : Autoimmune hepatitis in childhood : a 20-year experience. Hepatology 25 ; 541-547, 1997
PubMed
2) Manns MP, Czaja AJ, Gorham JD, et al. : Diagnosis and management of autoimmune hepatitis. Hepatology 51 ; 2193-2213, 2010
PubMed
3) Sogo T, Fujisawa T, Inui A, et al. : Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis. Hepatol Res 34 ; 187-192, 2006
PubMed
4) Alvarez F, Ciocca M, Canero-Velasco CC, et al. : Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 30 ; 222-227, 1999
 
5) Aw MM, Dhawan A, Samyn M, et al. : Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children : a 5-year follow-up. J Hepatol 51 ; 156-160, 2009
PubMed
6) Kanzler S, Gerken G, Lohr H, et al. : Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 34 ; 354-355, 2001
PubMed
7) Martin SR, Alvarez F, Anand R, et al. : Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transpl 17 ; 393-401, 2011
PubMed
8) Lindor KD : Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336 ; 691-695, 1997
 
9) Lindor KD, Kowdley KV, Luketic VA, et al. : Highdose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50 ; 808-814, 2009
PubMed
10) Miloh T, Arnon R, Shneider B, et al. : A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 7 ; 239-245, 2009
PubMed
11) Davies YK, Cox KM, Abdullah BA, et al. : Longterm treatment of primary sclerosing cholangitis in children with oral vancomycin : an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 47 ; 61-67, 2008
PubMed
12) Egawa H, Taira K, Teramukai S, et al. : Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation : a single center experience. Dig Dis Sci 54 ; 1347-1354, 2009
PubMed
13) Miloh T, Anand R, Yin W, et al. : Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl 17 ; 925-933, 2011
PubMed
P.113 掲載の参考文献
1) Czaja AJ, Carpenter HA, Lindor KD : Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis : a randomized placebo-controlled treatment trial. Hepatology 30 ; 1381-1386, 1999
PubMed
2) Nakamura K, Yoneda M, Yokohama S, et al. : Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 13 ; 490-495, 1998
PubMed
3) Miyake Y, Iwasaki Y, Kobashi H, et al. : Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int 3 ; 556-562, 2009
PubMed
4) Abe M, Mashiba T, Zeniya M, et al. : Present status of autoimmune hepatitis in Japan : a nationwide survey. J Gastroenterol 46 ; 1136-1141, 2011
PubMed
P.116 掲載の参考文献
1) Yoshizawa K, Matsumoto A, Ichijo T, et al. : Long-term outcome of Japanese patients with 1 autoimmune hepatitis. Hepatology 56 ; 68-76, 2012
 
2) Hino-Arinaga T, Ide T, Kuromatsu R, et al. : Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol 47 ; 569-576, 2012
PubMed
3) Rai T, Ohira H, Tojo J, et al. : Expression of human glucocorticoid receptor in lymphocytes of patients with autoimmune hepatitis. Hepatol Res 29 ; 148-152, 2004
PubMed
4) Tamori A, Shinzaki M, Kosaka S, et al. : Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Int 27 ; 95-100, 2007
PubMed
5) Takenami T, Sakaguchi K, Nishimura M, et al. : Therapeutic effects of azathioprine in combination with low-dose predonisolone in patients with intractable autoimmune hepatitis type 1. Acta Med Okayama 55 : 341-347, 2001
 
6) Yokokawa J, Kanno Y, Saito H, et al. : Risk factors associated with relapse of type 1 autoimmune hepatitis in Japan. Hepatology Res 41 ; 641-646, 2011
PubMed
P.119 掲載の参考文献
1) Hennes EM, Zeniya M, Czaja AJ, et al. : Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 ; 169-176, 2008
PubMed
2) Tanaka A, Harada K, Ebinuma H, et al. : Primary biliary cirrhosis-Autoimmune hepatitis overlap syndrome : A rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res 41 ; 877-886, 2011
PubMed
P.123 掲載の参考文献
1) Tiegs G, Hentschel J, Wendel A : A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90 ; 196-203, 1992
 
2) Longhi MS, Ma Y, Bogdanos DP, et al. : Impairment of CD4 (+) CD25 (+) regulatory T cells in autoimmune liver disease. J Hepatol 41 ; 31-37, 2004
PubMed
3) Kido M, Watanabe N, Okazaki T, et al. : Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD- 1-mediated signaling. Gastroenterology 135 ; 1333-1343, 2008
PubMed
4) Aoki N, Kido M, Iwamoto S, et al. : Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastroenterology 140 ; 1322-1333, 2011
PubMed
5) Iwamoto S, Kido M, Aoki N, et al. : IFN-γ is reciprocally involved in the concurrent development of organ-specific autoimmunity in the liver and stomach. Autoimmunity 45 ; 186-198, 2012
 
6) Iwamoto S, Kido M, Aoki N, et al. : TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL 20 expression. Clin Immunol 146 ; 15-25, 2013
 
7) Maruoka R, Aoki N, Kido M, et al. : Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology 145 ; 209-220, 2013
PubMed
P.126 掲載の参考文献
1) 徳永勝士 (編) : 人類遺伝学ノート-ゲノム医学・疾患感受性遺伝子探索の基礎-, 南山堂, 2007
 
2) 茶山一彰, 越智秀典, 三木大樹 : 肝疾患の疾患関連遺伝子-GWASを含めた最近の知見から-. 日消病会誌 110 ; 1577-1590, 2013
 
3) Hirschfield GM, Liu X, Xu C, et al. : Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 360 ; 2544-2555, 2009
PubMed
4) Liu X, Invernizzi P, Lu Y, et al. : Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 42 ; 658-660, 2010
PubMed
5) Mells GF, Floyd JAB, Morley KI, et al. : Genomewide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 43 ; 329-332, 2011
PubMed
6) Nakamura M, Nishida N, Kawashima M, et al. : Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 91 ; 721-728, 2012
PubMed
7) 中村稔 : PBCの疾患感受性遺伝子による病態の解明. 日消病会誌 110 ; 1602-1610, 2013
 
8) Liu JZ, Hov JR, Folseraas T, et al. : Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 45 ; 670-675, 2013
PubMed
9) Melum E, Franke A, Schramm C, et al. : Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 43 ; 17-19, 2011
PubMed
10) Liu JZ, Hov JR, Folseraas T, et al. : Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 45 ; 670-675, 2013
PubMed
P.130 掲載の参考文献
1) 戸田剛太郎 : 自己免疫性肝炎診断指針 1996. 肝臓 37 ; 298-300, 1996
 
2) Senaldi G, Portmann B, Mowat AP, et al. : Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child 67 ; 1447-1453, 1992
PubMed
3) Czaja AJ, Cookson S, Constantini PK, et al. : Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 117 ; 645-652, 1999
PubMed
4) Manns MP, Czaja AJ, Gorham JD, et al. : Diagnosis and management of autoimmune hepatitis. Hepatology 51 ; 2193-2213, 2010
PubMed
5) Longhi MS, Ma Y, Bogdanos DP, et al. : Impairment of CD4 (+) CD25 (+) regulatory T-cells in autoimmune liver disease. J Hepatol 41 ; 31-37, 2004
PubMed
6) Longhi MS, Hussain MJ, Mitry RR, et al. : Functional study of CD4+ CD25+ regulatoty-T cells in health and autoimmune hepatitis. J Immunol 176 ; 4484-4491, 2006
 
7) 日比紀文 : 自己免疫性肝炎の病態と予後の解明. 2009年度厚生労働科学研究費補助金 (難治性疾患克服研究事業) 研究協力報告書, 2009
 
8) Longhi MS, Liberal R, Holder B, et al. : Inhibition of Interleukin- 17 promotes differentiation of CD25- cells into stable T regulatory cells in patients with autoimmune hepatitis. Gastroenterology 142 : 1526-1535, 2012
PubMed
P.133 掲載の参考文献
1) Abe M, Mashiba T, Zeniya M, et al. : Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan. : Present status of autoimmune hepatitis in Japan : a nationwide survey. J Gastroenterol 46 ; 1136-1141, 2011
 
2) Kido M, Watanabe N, Okazaki T, et al. : Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD- 1-mediated signaling. Gastroenterology 135 ; 1333-1343, 2008
PubMed
3) Topalian SL, Hodi FS, Brahmer JR, et al. : Safety, activity, and immune correlates of anti-PD- 1 antibody in cancer. N Engl J Med 366 ; 2443-2454, 2012
PubMed
4) Matsumoto K, Miyake Y, Matsushita H, et al. : Antiprogrammed cell death- 1 antibody as a new serological marker for type 1 autoimmune hepatitis. J Gastroenterol Hepatol 29 ; 110-115, 2014
PubMed
5) 向井正也 : 全身性エリテマトーデスとヌクレオゾーム. Jpn J Clin Immunol 29 ; 127-135, 2006
 
6) Yokokawa J, Kanno Y, Abe K, et al. : Anti-nucleosome autoantibodies as markers for autoimmune hepatitis and their correlation with disease activity. Hepatol Res [in press]
 
7) Calich AL, Viana VS, Cancado E, et al. : Anti-ribosomal P protein : a novel antibody in autoimmune hepatitis. Liver Int 33 ; 909-913, 2013
PubMed

[ 薬物性肝障害編 ]

P.142 掲載の参考文献
1) 滝川一, 恩地森一, 高森頼雪 他 : DDW-J 2004 ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 ; 85-90, 2005
 
2) Takikawa H, Onji M : A proposal of the diagnostic scale of drug induced liver injury. Hepatol Res 2 ; 250-251, 2005
PubMed
3) 堀池典生, 村田洋介, 滝川一他 : 薬物性肝障害の実態-全国集計. 薬物性肝障害の実態, 中外医学社, 2008, p 1-10
 
4) Takikawa H, Murata Y, Horiike N, et al. : Drug induced liver injury in Japan : An analysis of 1676 cases between 1997 and 2006. Hepatol Res 39 ; 427-431, 2009
PubMed
5) Lewis JH, Kleiner D : Hepatic injury due to drugs, herbal compounds, chemicals and toxins. MacSween's Pathology of the Liver, Churchill Livingstone, 2012, p 645-760
 
6) Suk KT, Kim DJ : Drug-induced liver injury : present and future. Clin Mol Hepatol 18 ; 249-577, 2012
PubMed
7) Kawamori R, Kadowaki T, Onji M, et al. : PRACTICAL study group : Hepatic safety profile and glycemic control of pioglitazone in more than 20000 patinets with type 2 diabetes : postmarketing surveillance study in Japan. Diabetes Research and Clinical Practice 76 ; 229-235, 2007
 
8) 為田靭彦, 足立幸彦, 渡辺明治 : 薬物性肝障害の全国集計. 最新肝臓病学, 新興医学, 2001, p 50-61
 
9) 滝川一, 向坂彰太郎, 相磯光彦他 : 薬物性肝障害の最近の動向-2002-2006 年の366例の検討-肝臓 45 ; 517-521, 2007
 
10) 恩地森一, 滝川一, 村田洋介他 : 民間薬および健康食品による薬物性肝障害の調査. 肝臓 46 ; 142-148, 2005
 
11) Onji M, Fujioka S, Takeuchi Y, et al. : Clinical characteristics of drug-induced liver injury in the elderly. Hepatol Res 39 ; 546-552, 2009
PubMed
P.146 掲載の参考文献
1) Krahenbuhl S, Brauchli Y, Kummer O, et al. : Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage. Digestion 75 ; 232-237, 2007
PubMed
2) Shayiq RM, Roberts DW, Rothstein K, et al. : Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice : an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology 29 ; 451-463, 1999
PubMed
3) Thummel KE, Slattery JT, Ro H, et al. : Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 67 ; 591-599, 2000
PubMed
4) Suzuki A, Yuen N, Walsh J, et al. : Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol 7 ; 882-888, 2009
PubMed
5) de Abajo FJ, Montero D, Madurga M, et al. : Acute and clinically relevant drug-induced liver injury : a population based case-control study. Br J Clin Pharmacol 58 ; 71-80, 2004
PubMed
6) Lammert C, Einarsson S, Saha C, et al. : Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury : search for signals. Hepatology 47 ; 2003-2009, 2008
PubMed
7) Lucena MI, Andrade RJ, Kaplowitz N, et al. : Phenotypic characterization of idiosyncratic drug-induced liver injury : the influence of age and sex. Hepatology 49 ; 2001-2009, 2009
PubMed
8) Ghabril M, Chalasani N, Bjornsson E : Drug-induced liver injury : a clinical update. Curr Opin Gastroenterol 26 ; 222-226, 2010
PubMed
9) Lammert C, Bjornsson E, Niklasson A, et al. : Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 51 ; 615-620, 2010
PubMed
10) Russmann S, Kullak-Ublick GA, Grattagliano I : Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16 ; 3041-3053, 2009
PubMed
P.149 掲載の参考文献
1) 為田靭彦, 足立幸彦, 渡辺明治 : 薬剤性肝障害の全国調査. 最新肝臓病学 全国現状調査から将来展望まで, 新興医学出版社, 2001, 50-61
 
2) 佐田通夫, 久持顕子, 中沼安二他 : 痩せ薬・健康食品による薬物性肝障害二次全国調査集計結果. 肝臓 45 ; 96-108, 2004
 
3) Takikawa H, Murata Y, Horiike N, et al. : Druginduced liver injury in Japan : An analysis of 1676 cases between 1997 and 2006. Hepatol Res 39 ; 427-431, 2009
PubMed
4) 滝川一, 向坂彰太郎, 相磯光彦他 : 薬物性肝障害の最近の動向 2002-2006年の366例の検討. 肝臓 48 ; 517-521, 2007
 
5) 恩地森一, 滝川一, 村田洋介 他 : 民間薬および健康食品による薬物性肝障害の調査. 肝臓 46 ; 142-148, 2005
 
6) 神代龍吉, 古賀郁利子, 久持顕子他 : 消化器病患者における健康食品の摂取状況. 肝臓 44 ; 435-442, 2003
 
7) Kanda K, Kano T, Nagamine T : Use of Alternative Folk Medicine by Hepatoma Patients and the Associated Factors. The Kitakanto Med J 51 ; 307-311, 2001
 
8) 厚生労働省 : N-ニトロソ-フェンフルラミンの検出等について (http://www.mhlw.go.jp/houdou/2002/07/h0722-3.html)
 
9) 神代龍吉, 日野照子, 古賀郁利子 他 : やせ薬による薬物性急性肝炎. 肝臓 44 ; 113-116, 2003
 
10) Kawaguchi T, Harada M, Arimatsu H, et al. : Severe hepatotoxicity associated with a N-nitrosofenfluramine-containing weight-loss supplement : report of three cases. J Gastroenterol Hepatol 19 ; 349-350, 2004
 
P.152 掲載の参考文献
1) Padda MS, Sanchez M, Akhtar AJ, et al. : Drug-induced cholestasis. Hepatology 53 ; 1377-1387, 2011
PubMed
2) Desmet VJ : Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 26 ; 31-35, 1997
PubMed
3) 森井真也子, 目崎喜弘, 吉野裕顕 他 : 薬物起因性肝内胆管消失症候群 別冊日本臨牀 肝・胆道系症候群 (第2版) (I) 肝臓編 (上), 日本臨牀社, 2010, p 276-281
 
4) 滝川一, 恩地森一, 高森頼雪 他 : DDW-J 2004 ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 ; 85-90, 2005
 
5) 須藤俊之, 宮沢淳一, 渡辺康宏 : 薬物起因性肝内胆管消失症候群 別冊日本臨牀 肝・胆道系症候群 肝臓編 (下巻), 日本臨牀社, 1995, p59-62
 
P.156 掲載の参考文献
1) 滝川一, 恩地森一, 高森頼雪他 : DDW-J 2004 ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 ; 85-90, 2005
 
2) Takikawa H, Onji M : A proposal of the diagnostic scale of drug induced liver injury. Hepatol Res 32 ; 250-251, 2005
PubMed
3) 薬剤性肝障害の判定基準案. 薬物と肝 (第3回薬物と肝研究会記録), 杜稜印刷, 1978, p 96-98
 
4) Danan G, Benichou C : Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings : application to drug-induced liver injuries. J Clin Epidemiol 46 ; 1323-1330, 1993
 
5) 滝川一, 高森頼雪, 久持顕子他 : 新しい薬物性肝障害診断基準の提案-国際コンセンサス会議による診断基準の改定をもとに-. 肝臓 44 ; 176-179, 2003
 
P.161 掲載の参考文献
1) Lewis JH, Kleiner DE : Hepatic injury due to drugs, herbal compounds, chemicals and toxins. MacSween's Pathology of the Liver, 6 th ed., Chuchill Livingstone, 2012, 645-760
 
2) 中沼安二, 原田憲一, 任香善他 : 薬物性肝障害 b) 病理. 病理と臨床 27 ; 764-769, 2009
 
3) 福里俊夫, 大部誠 : 薬物性肝障害, 中毒性肝障害. 肝臓病理テキスト, 南江堂, 2013, 121-130
 
P.164 掲載の参考文献
1) Kaplowitz N, DeLeve LD, eds. : Drug-induced Liver Disease, Marcel Dekker, Inc., 2003
 
2) Schiff ER, Sorrell MF, Maddrey WC, eds. : SCHIFF'S DISEASES OF THE LIVER, TENTH EDITION, Lippincott Williams & Wilkins, 2007
 
3) 松崎靖司, 西川清広 : 薬物性肝障害の治療-EBMに基づくUDCAの効果. 日消病会誌 100 ; 659-666, 2003
 
P.167 掲載の参考文献
1) Chalasani N, Bjornsson E : Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138 ; 2246-2259, 2010
PubMed
2) 滝川一, 恩地森一, 高森頼雪 他 : DDW-J 2004 ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 ; 85-90, 2005
 
3) Danan G, Benichou C : Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings : application to drug-induced liver injuries. J Clin Epidemiol 46 ; 1323-1333, 1993
 
4) 堀池典生, 村田洋介, 滝川一他 : 薬物性肝障害の実態-全国調査-. 薬物性肝障害の実態, 中外医学社, 2008, p 1-10
 
5) Chen M, Borlak J, Tong W : High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58 ; 388-396, 2013
PubMed
6) Daly AK, Day CP : Genetic association studies in drug-induced liver injury. Drug Metab Rev 44 ; 116-126, 2012
PubMed
7) Daly AK, Donaldson PT, Bhatnagar P, et al. : HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41 ; 816-819, 2009
 
8) Watanabe I, Tomita A, Shimizu M, et al. : A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 73 ; 435-455, 2003
PubMed
9) Huang YS, Chern HD, Su WJ, et al. : Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37 ; 924-930, 2003
PubMed
10) Azuma J, Ohno M, Kubota R, et al. : NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month fourdrug standard treatment of tuberculosis : a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 69 ; 1091-1101, 2013
PubMed
P.172 掲載の参考文献
1) Krawitt EL : Autoimmune hepatitis. N Engl J Med 354 ; 54-66, 2006
PubMed
2) Zen Y, Notsumata K, Tanaka N, et al. : Hepatic centrilobular zonal necrosis with positive antinuclear antibody : a unique subtype or early disease of autoimmune hepatitis? Hum Pathol 38 ; 1669-1675, 2007
PubMed
3) Liu ZX, Kaplowitz N : Immune-mediated drug-induced liver disease. Clin Liver Dis 6 ; 755-774, 2002
PubMed
4) 高橋宏樹, 銭谷幹男 : 自己免疫性肝炎の発症機構. 消化器と免疫 46 ; 20-31, 2009
 
5) Alla V, Abraham J, Siddiqui J, et al. : Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 40 ; 757-761, 2006
PubMed
6) Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. : Drug-induced autoimmune hepatitis : clinical characteristics and prognosis. Hepatology 51 ; 2040-2048, 2010
PubMed
7) 森岡千恵, 植村正人, 守屋圭他 : 最近の薬物性肝障害の多様性 : 特に自己免疫性肝炎発症との関連について. 薬物性肝障害の実態, 中外医学社, 2008, 66-76
 
8) Abe K, Kanno Y, Okai K, et al. : Centrilobular necrosis in acute presentation of Japanese patients with type 1 autoimmune hepatitis. World J Hepatol 4 ; 262-267, 2012
PubMed
9) Takahashi A, Kanno Y, Takahashi Y, et al. : Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis : a case report. World J Gastroenterol 14 ; 5474-5477, 2008
PubMed
10) 大平弘正, 阿部和道, 高橋敦史他 : 自己免疫性肝炎の発症誘因としての先行疾患薬物性肝障害とウイルス感染. 肝胆膵 7 ; 43-49, 2009
 

[ 急性肝不全編 ]

P.181 掲載の参考文献
1) 犬山シンポジウム記録刊行会 : 劇症肝炎の診断基準. A 型肝炎, 劇症肝炎 : 第12回犬山シンポジウム, 中外医学社, 1982, pp 110-230
 
2) Trey C, Davidson CS : The management of fulminant hepatic failure. Progress in Liver Diseases 3 ; 282-298, 1970
PubMed
3) Polson J, Lee WM : AASLD position paper : The management of acute liver failure. Hepatology 41 ; 1179-1197, 2005
PubMed
4) 持田智, 滝川康裕, 中山伸朗他 : 我が国における「急性肝不全」の概念, 診断基準の確立 : 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究」班, ワーキンググループ-1, 研究報告. 肝臓 52 ; 393-398, 2011
 
5) Mochida S, Takikawa Y, Nakayama N, et al. : Diagnostic Criteria of Acute Liver Failure : A Report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 41 ; 805-812, 2011
 
6) Sugawara K, Nakayama N, Mochida S : Acute liver failure in Japan : definition, classification, and prediction of the outcome. J Gastroenterol 47 ; 849-861, 2012
PubMed
7) Bergstrand H : Uber die akute gelbe Leberatrophie, mit besonderer Berucksichtigung ihras Auftretens in Schweden in Jahre 1927. Acta Medica Scandinavica, 74 ; 331-338, 1930
 
8) Lucke B, Mallory T : The fulminant form of epidemic hepatitis. Am J Pathol 22 ; 867-943, 1946
 
9) Mathiesen LR, Skinoj P, Nielsen JO, et al. : Hepatitis type A, B, and non-A non-B in fulminant hepatitis. Gut 21 ; 72-77, 1980
 
10) Trey C, Lipworth L, Chalmers TC, et al. : Fulminant hepatic failure ; presumable contribution to halothane. N Engl J Med 279 ; 798-801, 1968
PubMed
11) Tandon BN, Joshi YK, Krishnamurthy L, et al. : Subacute hepatic failure ; is it a distinct entity? J Clin Gastroenterol 4 ; 343-346, 1982
PubMed
12) Gimson AE, O'Grady JG, Ede RJ, et al. : Late onset hepatic failure : clinical, serological and histological features. Hepatology 6 ; 288-294, 1986
 
13) Bernauau J, Rueff B, Benhamou JP : Fulminant and subfulminant liver failure : definitions and causes. Semin Liver Dis 6 ; 97-106, 1986
 
14) O'Grady JG, Schaim SW, Williams R : Acute Liver Failure : Remodeling the Syndromes. Lancet 342 ; 273-275, 1993
 
15) Tandon BN, Bernauau J, O'Grady JG, et al. : Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol 14 ; 403-404, 1999
 
16) Fujiwara K, Mochida S, Matsui A, et al. : Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 38 ; 646-657, 2008
PubMed
17) 持田智, 滝川康裕, 中山伸朗他 : 急性肝不全の成因分類. 肝臓, 2014 [in press]
 
18) Mochida S, Takikawa Y, Nakayama N, et al. : Classification of the etiologies of acute liver failure in Japan : A report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res, 2014 [in press]
 
P.187 掲載の参考文献
1) Mochida S, Takikawa Y, Nakayama N, et al. : Diagnostic criteria of acute liver failure : A report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 41 ; 805-812, 2011
 
2) Sugawara K, Nakayama N, Mochida S : Acute liver failure in Japan-definition, classification and prediction of the outcome. J Gastroenterol 47 ; 849-861, 2012
PubMed
3) 坪内博仁, 桶谷真, 井戸章雄他 : 劇症肝炎及び遅発性肝不全 (LOHF : late onset hepatic failure) の全国集計 (2009年). 厚生労働科学研究費補助金難治性疾患克服研究事業 難治性の肝・胆道疾患に関する調査研究 平成22年度研究報告書, 2011, 96-113
 
4) Oketani M, Ido A, Nakayama N, et al. : Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan : Summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 43 ; 97-105, 2013
PubMed
5) Fujiwara K, Mochida S, Matsui A, et al. : Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 38 ; 646-657, 2008
PubMed
6) Oketani M, Ido A, Uto H, et al. : Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 41 ; 805-812, 2011
PubMed
7) Yamashiki N, Sugawara Y, Tamura S, et al. : Outcome after living donor liver transplantation for acute liver failure in japan ; results of a nationwide survey. Liver Transpl 18 ; 1069-1077, 2012
PubMed
P.194 掲載の参考文献
1) 犬山シンポジウム記録刊行会 : 劇症肝炎の診断基準. A型肝炎, 劇症肝炎 : 第12回犬山シンポジウム, 中外医学社, 1982, p 110-230
 
2) Fujiwara K, Mochida S, Matsui A, et al. : Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 38 ; 646-657, 2008
PubMed
3) Oketani M, Ido A, Nakayama N, et al. : Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan : Summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 43 ; 97-105, 2013
PubMed
4) Polson J, Lee WM : AASLD position paper : the management of acute liver failure. Hepatology 41 ; 1179-1197, 2005
PubMed
5) 持田智, 滝川康裕, 中山伸朗他 : 我が国における「急性肝不全」の概念, 診断基準の確立 : 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究」班, ワーキンググループ-1, 研究報告. 肝臓 52 ; 393-398, 2011
 
6) Mochida S, Takikawa Y, Nakayama N, et al. : Diagnostic criteria of acute liver failure : A report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 41 ; 805-812, 2011
 
7) Sugawara K, Nakayama N, Mochida S : Acute liver failure in Japan : definition, classification, and prediction of the outcome. J Gastroenterol 47 ; 849-861, 2012
PubMed
8) 持田智, 中山伸朗 : 我が国における急性肝不全および遅発性肝不全 (LOHF) の実態 (2011年). 平成23年度全国調査. 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究班」平成23年度報告書, 2012, p 101-112
 
9) 持田智, 中山伸朗 : 我が国における急性肝不全および遅発性肝不全 (LOHF) の実態 (2012年) : 平成24年度全国調査. 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究班」平成24年度報告書, 2013, p 108-124
 
10) Oketani M, Ido A, Uto H, et al. : Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42 ; 627-636, 2012
PubMed
11) 坪内博仁, 熊田博光, 清澤研道 他 : 免疫抑制・化学療法により発症するB 型肝炎対策 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告. 肝臓 50 ; 38-42, 2009
 
P.199 掲載の参考文献
1) 日本肝臓学会 (編) : B型肝炎治療ガイドライン (第1. 2版) (https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/)
 
2) Oketani M, Ido A, Uto H, et al. : Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 41 ; 805-812, 2011
PubMed
3) Hui CK, Cheung WW, Zhang HY, et al. : Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 ; 59-68, 2006
PubMed
4) Kusumoto S, Tanaka Y, Mizokami M, et al. : Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90 ; 13-23, 2009
PubMed
5) 田中榮司 : 【肝炎診療の新たな展開】De novo B型肝炎の臨床像と予防. 綜合臨床 60 ; 26-30, 2011
 
6) Evens AM, Jovanovic BD, Su YC, et al. : Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases : meta-analysis and examination of FDA safety reports. Ann Oncol 22 ; 1170-1180, 2011
PubMed
7) Kusumoto S, Tanaka Y, Ueda R, et al. : Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 46 ; 9-16, 2011
PubMed
8) Umemura T, Tanaka E, Kiyosawa K, et al. : Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47 : e 52-56, 2008
 
P.203 掲載の参考文献
1) 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 難治性の肝・胆道疾患に関する調査研究. 平成24年度総括・分担研究報告書, 2013
 
2) Dervite I, Hober D, Morel P : Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344 ; 68-69, 2001
 
3) Suzuki K, Aikawa T, Okamoto H : Fulminant hepatitis E in Japan. N Engl J Med 347 ; 1455-1456, 2002
 
4) Alvarez F, Berg PA, Bianchi FB, et al. : International autoimmune hepatitis group report : review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 ; 929-938, 1999
PubMed
5) 滝川一, 恩地森一, 高森頼雪他 : DDW-J ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 ; 85-89, 2005
 
6) Ebert EC : Hypoxic liver injury. Mayo Clin Proc 81 ; 1232-1236, 2006
PubMed
P.208 掲載の参考文献
1) 持田智, 滝川康裕, 中山伸朗他 : 我が国における「急性肝不全」の概念, 診断基準の確率 : 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝胆道疾患に関する調査研究」班, ワーキンググループ-1, 研究報告. 肝臓 52 ; 393-398, 2011
 
2) Takikawa Y, Endo R, Suzuki K, et al. : Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. Dig Dis Sci 51 ; 359-364, 2006
PubMed
3) 滝川康裕, 宮本康弘 : 肝胆膵領域のEBM Update 2012 劇症肝炎 (急性肝不全). 肝胆膵 64 ; 297-307, 2012
 
4) 持田智 : 我が国における急性肝不全および遅発性肝不全 (LOHF) の実態 (2011年) -平成24年度全国調査. 厚生労働科学研究費補助金 (難治性の肝疾患克服研究事業), 平成24年度報告書, 2013, p 108-124
 
5) Oketani M, Ido A, Nakayama N, et al. : Etiology and prognosis of fulminant hepatitis and late onset hepatic failure in Japan : summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 43 ; 97-105, 2013
PubMed
6) Takikawa Y, Endo R, Suzuki K, et al. : Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan. J Hepatol 51 ; 1021-1029, 2009
PubMed
7) 犬山シンポジウム記録刊行会 : A型肝炎・劇症肝炎. 第12回犬山シンポジウム, 中外医学社, 1982, p 110-230
 
8) 滝川康裕, 鈴木一幸 : 急性肝炎の予知は可能か. 肝胆膵 59 ; 459-467, 2009
 
P.212 掲載の参考文献
1) 持田智, 滝川康裕, 中山伸朗他 : 我が国における「急性肝不全」の概念, 診断基準の確立 : 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究」班, ワーキンググループ-1, 研究報告. 肝臓 52 ; 393-398, 2011
 
2) 杉原潤一, 内藤智雄, 石木佳英他 : わが国における劇症肝炎の予後予測と肝移植の適応に関する多施設研究. 肝臓 42 ; 543-557, 2001
 
3) Mochida S, Nakayama N, Matsui A, et al. : Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res 38 ; 970-979, 2008
 
4) 井上和明, 山田雅也, 与芝真 : 劇症肝炎診療の進歩. 治療 : 劇症肝炎の内科治療. 肝胆膵 42 ; 475-481, 2001
 
5) 北村信哉, 平澤博之, 菅井桂雄他 : 劇症肝炎の予知法. 診断基準, 予後評価の再検討. 肝臓 40 ; 170-172, 1999
 
6) O'Grady JG, et al. : Outcome of orthotopic liver transplantation in the aetiological and clinical variants of acute liver failure. Q J Med 68 ; 817-824, 1988
PubMed
7) Bernuau J, Sammuel D, Durand F, et al. : Criteria for emergency liver transplantation in patients with acute viral hepatitis and factor V below 50% of normal. Hepatology 14 ; 49, 1991
 
8) Fikatas P, Lee JE, Sauer IM, et al. : APACHE III Score Is Superior to King's College Hospital Criteria, MELD score and APACHE II Score to Predict Outcomes After Liver Transplantation for Acute Liver Failure. Transplant Proc 45 ; 2295-2301, 2013
 
9) Naiki T, Nakayama N, Mochida S, et al. : Novel scoring system as a useful model to predict the outcome of patients with acute liver failure : Application to indication criteria for liver transplantation. Hepatol Res 42 ; 68-75, 2012
PubMed
10) 持田智 : 劇症肝炎 わが国における問題点. 肝臓 50 ; 497-506, 2009
 
P.218 掲載の参考文献
1) 持田智, 中山伸朗, 坪内博仁 : 我が国における急性肝不全および遅発性肝不全 (LOHF) の実態 (2011年). 難治性の肝・胆道疾患に関する調査研究 平成24年度 総括・分担研究報告書, 2013, 108-124
 
2) Yasui S, Fujiwara K, Okitsu K, et al. : Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res 42 ; 42-50, 2012
PubMed
3) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 (編) : 劇症肝炎の診療ガイド, 文光堂, 2010
 
4) Fujiwara K, Yasui S, Yonemitsu Y, et al. : Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. Hepatol Res, 2013 [Epub ahead of print]
 
5) Fujiwara K, Yasui S, Okitsu K, et al. : The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol 45 ; 1255-1262, 2010
PubMed
P.222 掲載の参考文献
1) Inoue K, Watanabe T, Maruoka N, et al. : Japanesestyle intensive medical care improves prognosis for acute liver failure and the perioperative management of liver transplantation. Transplant Proc 42 ; 4109-4112, 2010
PubMed
2) Yoshiba M, Inoue K, Sekiyama K, et al. : Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artif Organs 20 ; 1169-1172, 1996
PubMed
3) Inoue K, Kourin A, Watanabe T, et al. : Plasma exchange in combination with online-hemodiafiltration as a promising method for purifying the blood of fulminant hepatitis patients. Hepatol Res 38 Suppl 1 ; S46-51, 2008
 
4) 与芝真, 三條健昌, 井上昇他 : 急性肝不全に対する血漿交換療法の効果と限界. 日消病会誌 77 ; 1397-1402, 1980
 
5) 与芝真, 井上和明 : エビデンスに基づく血漿交換療法の評価. 日本輸血学会誌 48 ; 9-26, 2002
 
6) Inoue K, Yoshida M : Overview of Artificial Liver Support Systems in the World and New Promising Methods. Liver Failure, Nova Publishers, 2013, 159-176
 
7) Inoue K, Kourin A, Watanabe T, et al. : Artificial liver support system using large buffer volumes removes significant glutamine and is an ideal bridge to liver transplantation. Transplant Proc 41 ; 259-261, 2009
PubMed
P.226 掲載の参考文献
1) 日本肝移植研究会 : 肝移植症例登録報告. 移植 46 ; 524-536, 2011
Medical*Online
2) 持田智 : 劇症肝炎 : わが国における問題点. 肝臓 50 ; 497-506, 2009
 
3) Kaido T, Egawa H, Tsuji H, et al. : In-hospital mortality in adult recipients of living donor liver transplantation : experience of 576 consecutive cases at a single center. Liver Transpl 15 ; 1420-1425, 2009
 
4) Kaido T, Ogura Y, Hata K, et al. : Effects of posttransplant enteral nutrition with an immunomodulating diet containing hydrolyzed whey peptide after liver transplantation. World J Surg 36 ; 1666-1671, 2012
PubMed
5) Kaido T, Ogawa K, Ogura Y, et al. : Liver transplantation in adults with acute liver failure : a single center experience over a period of 15 years. Hepatogastroenterology [in press]
 
P.229 掲載の参考文献
1) 藤原慶一, 横須賀收, 織田成人他 : 「難治性の肝・胆道疾患に関する調査研究」班 劇症肝炎分科会 血液浄化法の有効性評価を目的としたワーキンググループ. 急性肝不全に対する血液浄化療法の有効性評価 : 急性肝不全に対する人工肝補助療法の現状に関するアンケート調査報告. 肝臓 53 ; 530-533, 2012
 
2) Yokoi T, Oda S, Shiga H, et al. : Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. Transfus Apher Sci 40 ; 61-70, 2009
PubMed
3) 荒田慎寿, 森脇義弘, 高山和久他 : 急性肝不全に対するon-line hemodaiafiltrationを用いた人工肝補助療法の確立. 肝臓 53 ; 7-17, 2012
 
4) 秋葉隆, 川西秀樹, 峰島三千男他 : 透析液水質基準と血液浄化器性能評価基準 2008. 日本透析医学会雑誌 41 ; 159-167, 2008
 
P.232 掲載の参考文献
1) Mita A, Hashikura Y, Tagawa Y, et al. : Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Am J Gastroenterol 100 ; 2551-2559, 2005
PubMed
2) Leifeld L, Nattermann J, Fielenbach M, et al. : Intrahepatic activation of caspases in human fulminant hepatic failure. Liver Int 26 ; 872-879, 2006
PubMed
3) Ryo K, Kamogawa Y, Ikeda I, et al. : Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 95 ; 2047-2055, 2000
PubMed
4) Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. : Lethal effect of the anti-Fas antibody in mice. Nature 364 ; 806-809, 1993
PubMed
5) Kaufmann T, Jost PJ, Pellegrini M, et al. : Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase- 8 and involves the BH 3-only proteins Bid and Bim. Immunity 30 ; 56-66, 2009
 
6) Wei M, Zong W, Cheng E, et al. : Proapoptotic BAX and BAK : a requisite gateway to mitochondrial dysfunction and death. Science 292 ; 727-730, 2001
 
7) Yin X, Wang K, Gross A, et al. : Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400 ; 886-891, 1999
PubMed
8) Hikita H, Takehara T, Kodama T, et al. : Delayedonset caspase-dependent massive hepatocyte apoptosis upon Fas activation in Bak/Bax-deficient mice. Hepatology 54 ; 240-251, 2011
 
9) Jost PJ, Grabow S, Gray D, et al. : XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460 ; 1035-1039, 2009
PubMed
P.235 掲載の参考文献
1) Fujiwara K, Okita K, Akamatsu K, et al. : Antithrombin III concentrate in the treatment of fulminant hepatic failure. Gastroenterol Jpn 23 ; 423-427, 1988
PubMed
2) Mori W, Shiga J, Kato A : Extensive hepatic cell necrosis produced by the Shwartzman mechanism. Virchows Arch A Pathol Anat Histol 382 ; 179-189, 1979
PubMed
3) 福井博他 : 急性肝不全病態におけるエンドトキシン血症の意義. 肝疾患あすの話題, 中外医学社, 1985, 95-99
 
4) Muto Y, Nouri-Aria KT, Meager A, et al. : Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2 ; 72-74, 1988
PubMed
5) 大西弘生, 武藤泰敏 : 劇症肝炎の発症機序. 箱根シンポジウム記録 肝不全・胆汁分泌・磁気共鳴分光法, 中外医学社, 1993, 2-9
 
6) Mochida S, Ogata I, Ohta Y, et al. : In situ evaluation of the stimulatory state of hepatic macrophages based on their ability to produce superoxide anions in rats. J Pathol 158 ; 67-71, 1989
PubMed
7) Mochida S, Ogata I, Hirata K, et al. : Provocation of massive hepatic necrosis by endotoxin after partial hepatectomy in rats. Gastroenterology 99 ; 771-777, 1990
PubMed
8) Arai M, Mochida S, Ohno A, et al. : Sinusoidal endothelial cell damage by activated macrophages in rat liver necrosis. Gastroenterology 104 ; 1466-1471, 1993
PubMed
9) Mochida S, Arai M, Ohno A, et al. : Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 29 ; 1532-1540, 1999
PubMed
10) Taniguchi E, Sakisaka S, Matsuo K, et al. : Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 49 ; 121-130, 2001
PubMed
11) Namisaki T, Yoshiji H, Kojima H, et al. : Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats. J Hepatol 44 ; 568-575, 2006
PubMed
12) 福井博 : 急性肝不全におけるADAMTS13の動態. 平成22年度 厚生労働省「難治性の肝・胆道疾患に関する調査研究班」報告書, 2011
 
P.240 掲載の参考文献
1) Riehle KJ, Dan YY, Campbell JS, et al. : New concepts in liver regeneration. J Gastroenterol Hepatol 26 ; 203-212, 2011
PubMed
2) Gohda E, Tsubouchi H, Nakayama H, et al. : Purification and partial characterization of hepatocyte growth factor from plasma of patients with fulminant hepatic failure. J Clin Invest 888 ; 414-419, 1988
 
3) Huh CG, Factor VM, Sanchez A, et al. : Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101 ; 4477-4482, 2004
PubMed
4) Nakamura K, Nonaka H, Saito H, et al. : Hepatocyte proliferation and tissue remodeling is impared after liver injury in oncostatin M receptor knockout mice. Hepatology 39 ; 635-644, 2004
 
5) Ogiso T, Nagaki M, Takai S, et al. : Granulocyte colony-stimulating factor impairs liver regeneration in mice through the up-regulation of interleukin-1 beta. J Hepatol 47 ; 816-825, 2007
PubMed
6) Nagaki M, Sugiyama A, Naiki T, et al. : Control of cyclin-dependent kinase inhibitors, p 21 and p 27, and cell cycle progression in rat hepatocytes by extracellular matrix. J Hepatol 32 ; 488-496, 2000
 
7) Kimata T, Nagaki M, Ogiso T, et al. : Actin organization and hepatocyte differentiation are regulated by extracellular matrix via PI-4, 5-bisphosphate in the rat. Hepatology 44 ; 140-151, 2006
PubMed
8) Wuestefeld T, Pesic M, Rudalska R, et al. : A direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell 153 ; 389-401, 2013
PubMed
9) Beyer TA, Xu W, Teupser D, et al. : Impaired liver regeneration in Nrf2 knockout mice : role of ROSmediated insulin/IGF- 1 resistance. EMBO J 27 ; 212-223, 2008
PubMed
10) Sun R, Gao B : Negative regulation of liver regeneration by innate immunity (Natural killer cells/interferon-γ). Gastroenterology 127 ; 1525-1539, 2004
 
11) Katoonizadeh A, Nevens F, Verslype C, et al. : Liver regeneration in acute severe liver impairment : a clinicopathological correlation study. Liver Intern 26 ; 1225-1233, 2006
 
12) Boulter L, Govaere O, Bird TG, et al. : Macrophagederived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med 18 ; 572-579, 2012
PubMed
13) Conboy IM, Conboy MJ, Wagers AJ, et al. : Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433 ; 760-764, 2005
 
P.243 掲載の参考文献
1) Gohda E, Tsubouchi H, Nakayama H, et al. : Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 81 ; 414-419, 1988
PubMed
2) Miyazawa K, Tsubouchi H, Naka D, et al. : Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun 163 ; 967-973, 1989
PubMed
3) Miyazawa K, Shimomura T, Kitamura A, et al. : Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 268 ; 10024-10028, 1993
PubMed
4) Moriuchi A, Hirono S, Ido A, et al. : Additive and inhibitory effects of simultaneous treatment with growth factors on DNA synthesis through MAPK pathway and G1 cyclins in rat hepatocytes. Biochem Biophys Res Commun 280 ; 368-373, 2001
PubMed
5) Hasuike S, Ido A, Uto H, et al. : Hepatocyte growth factor accelerates the proliferation and differentiation of hepatic oval cells in a 2-acetylaminofluorene/partial hepatectomy model in rats. J Gastroenterol Hepatol 20 ; 1753-1761, 2005
 
6) Kosai K, Matsumoto K, Nagata S, et al. : Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 244 ; 683-690, 1998
PubMed
7) Kosai K, Matsumoto K, Funakoshi H, et al. : Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 30 ; 151-159, 1999
PubMed
8) Giebeler A, Boekschoten MV, Klein CA, et al. : c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology 137 ; 297-308, 2009
 
9) Ido A, Moriuchi A, Numata M, et al. : Safety and pharmacokinetics of recombinant human hepatocyte growth factor in patients with fulminant hepatitis : a phase I/II clinical trial, following preclinical studies to ensure safety. J Transl Med 9 ; 55, 2011
PubMed
10) Kim ID, Azuma T, Ido A, et al. : Navigator-echobased MR provides high resolution images and precise volumetry of swine livers without breath holding or injection of contrast media. Liver Transplant 12 ; 72-77, 2006
PubMed
P.246 掲載の参考文献
1) Takami T, Terai S, Sakaida I : Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol 28 ; 203-208, 2012
PubMed
2) Garg V, Garg H, Khan A, et al. : Granulocyte colonystimulating factor mobilizes CD34 (+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 142 ; 505-512, 2012
PubMed
3) Zhang L, Kang W, Lei Y, et al. : Granulocyte colony-stimulating factor treatment ameliorates liver injury and improves survival in rats with D-galactosamineinduced acute liver failure. Toxicol Lett 204 ; 92-99, 2011
 
4) Caraceni P, Giannone F, Catani L, et al. : Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. Dig Liver Dis 39 ; 943-951, 2007
 
5) Belardinelli MC, Pereira F, Baldo G, et al. : Adult derived mononuclear bone marrow cells improve survival in a model of acetaminophen-induced acute liver failure in rats. Toxicology 247 ; 1-5, 2008
 
6) Jin SZ, Meng XW, Sun X, et al. : Hepatocyte growth factor promotes liver regeneration induced by transfusion of bone marrow mononuclear cells in a murine acute liver failure model. J Hepatobiliary Pancreat Sci 18 ; 397-405, 2011
 
7) Li J, Zhang L, Xin J, et al. : Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs. Hepatology 56 ; 1044-1052, 2012
 
8) Gruttadauria S, Grosso G, Pagano D, et al. : Marrowderived mesenchymal stem cells restore biochemical markers of acute liver injury in experimental model. Transplant Proc 45 ; 480-486, 2013
PubMed
9) van Poll D, Parekkadan B, Cho CH, et al. : Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47 ; 1634-1643, 2008
PubMed
10) Moslem M, Valojerdi MR, Pournasr B, et al. : Therapeutic potential of human induced pluripotent stem cell-derived mesenchymal stem cells in mice with lethalfulminant hepatic failure. Cell Transplant 22 ; 1785-1799, 2013
PubMed
P.251 掲載の参考文献
1) Mochida S, Nakayama N, Matsui A, et al. : Reevaluation of the guideline published by the acute liver failure study group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res 38 ; 970-979, 2008
 
2) Naiki T, Nakayama N, Mochida S, et al. : Novel scoring system as a useful model to predict the outcome of patients with acute liver failure : Application to indication criteria for liver transplantation. Hepatol Res 42 ; 68-75, 2012
PubMed
3) Nakayama N, Oketani M, Kawamura Y, et al. : Algorithm to determine the outcome of patients with acute liver failure : A data mining analysis using decision trees. J Gastroenterol 47 ; 664-677, 2012
PubMed
4) Fujiwara K, Mochida S, Matsui A, et al. : Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 38 ; 646-657, 2008
PubMed
5) Oketani M, Ido A, Nakayama N, et al. : Etiology and prognosis of fulminant hepatitis and lateonset hepatic failure in Japan : Summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 43 ; 97-105, 2013
PubMed
6) Nakayama N, Oketani M, Kawamura Y, et al. : Novel classification of acute liver failure through clustering using a self-organizing map : Usefulness for prediction of the outcome. J Gastroenterol 46 ; 1127-1135, 2011
PubMed

[ その他の肝疾患編 ]

P.257 掲載の参考文献
1) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会 (編) : 急性胆管炎・胆嚢炎診療ガイドライン 2013, 医学図書出版株式会社, 2013
 
2) 金子健一朗, 安藤久實 : 先天性胆道拡張症と肝内結石. 胆と膵 24 ; 759-762, 2003
Medical*Online
3) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 (編) : 肝内結石症の診療ガイド, 文光堂, 2011
 
4) 日本消化器病学会 (編) : 胆石症診療ガイドライン, 南江堂, 2009
 
5) 荒井俊彦 : 当院人間ドック受診者の腹部超音波所見. 健康医学 15 ; 175-178, 2000
 
6) 竹内和男, 桑山美知子, 辻裕之他 : 当院人間ドックにおける腹部超音波診断の現状. 超音波医学 35 ; 521-527, 2008
Medical*Online
7) 二村雄次, 籾山正人, 山田達治他 : 重症度分類からみた日本人における肝内結石症の実態とその分析. 厚生省特定疾患消化器系疾患調査研究班肝内結石症分科会 平成12年度研究報告書, 2001, 33-38
 
8) 土屋慎, 露口利夫, 酒井裕司他 : 当院における末梢型肝内結石の診療-無症状症例の取り扱い-. 胆と膵 28 ; 505-508, 2007
Medical*Online
P.261 掲載の参考文献
1) 木下博昭 : 肝内結石をめぐる諸問題 最近5年間の疫学的統計. 日臨外 37 ; 129-132, 1976
 
2) 谷村弘 : 成分分析からみた肝内結石の成因. 胆道 11 ; 237-248, 1997
Medical*Online
3) 内藤剛, 亀田智統, 鈴木克彦他 : 肝内結石症の成因 ; ビリルビンカルシウム石. 消化器外科 21 ; 1431-1436, 1998
 
4) 田妻進, 梶山梧郎 : 肝内結石症の成因 ; コレステロール胆石. 消化器外科 21 ; 1437-1441, 1998
 
5) Nakanuma Y, Yamaguchi K, Ohta G, et al. : Pathological features of hepatolithiasis in Japan. Hum Patho 9 ; 1181-1186, 1998
 
6) Nakanuma Y, Terada T, Nakagawa T, et al. : Pathology of hepatolithiasis with biliary malformation in Japan. Liver 8 ; 287-292, 1998
 
7) 藤尾俊之, 大坪光次, 菅和男他 : 兄妹に見られた肝内結石症について. 胆と膵 12 ; 77-81, 1991
 
8) 古川正人, 古井純一郎, 八坂貴宏他 : 肝内結石症の時代変遷-五島列島における特殊性-. 胆と膵 15 ; 409-413, 1994
 
9) 八坂貴宏, 佐野信也 : Case-control studyからみた肝内結石症の成因. 胆と膵 28 ; 483-489, 2007
Medical*Online
10) 古賀暉人 : 細胆管炎, 低γ-グロブリン血症を初発としたATL患者. 日本内科学会雑誌 76 ; 477, 1987
 
11) Takegoshi K, Nakanuma Y, Tsukada K, et al. : Human T-Lymphotrophic Virus type I-associated myelopathy and primary sclerosing cholangitis. J Clin Gastroenterol 13 ; 202-204, 1991
 
12) 笹田哲朗, 薄井裕治, 高林有道他 : 肝内および胆嚢内結石の形成におけるレドックス制御異常の関与についての検討. 消化器と免疫 32 ; 141-144, 1996
 
P.265 掲載の参考文献
1) 中山文夫 : 疫学分科会報告. 厚生省特定疾患対策 昭和60年度 肝内結石症調査研究班報告書 (班長中山文夫), 1985, 7-24
 
2) 小澤和恵, 小林展章, 高林有道他 : 肝内結石症に関する全国調査報告. 厚生省特定疾患対策 肝内結石症調査研究班 平成元年度 研究報告書 (班長小澤和恵), 1989, 11-39
 
3) 永井正規, 内山和久, 石本喜和男他 : 肝内結石症全国調査集計. 厚生省特定疾患 肝内結石症調査研究班 平成5年度 研究報告書 (班長谷村弘), 1993, 13-27
 
4) 谷村弘, 内山和久, 石本喜和男 : 肝内結石症の全国疫学調査 (II) -最近の動向と10年後のQOLについて-. 厚生省特定疾患 肝内結石症調査研究班 平成7年度研究報告書 (班長谷村弘), 1995, 11-19
 
5) 馬場園明, 林櫻松, 玉腰暁子他 : 肝内結石症の全国受療患者の推計と臨床疫学的特性. 厚生省特定疾患 消化器系疾患調査研究班 肝内結石症分科会 平成11年度研究報告書 (分科会長二村雄次), 1999, 9-14
 
6) 森俊幸 : 肝内結石症全国調査. 厚生労働省科学研究費補助金 特定疾患対策研究事業 肝内結石症に関する調査研究 平成17-19 年度総括・分担研究報告書 (班長跡見裕), 2007, 18-22
 
7) Suzuki Y, Mori T, Abe N, et al. : Predictive factors for cholangiocarcinoma associated with hepatolithiasis determined on the basis of Japanese multicenter study. Hepatol Res 42 ; 166-170, 2012
PubMed
8) 森俊幸 : 肝内結石症のコホート調査. 厚生労働省難治性疾患克服研究事業 難治性の肝・胆道疾患に関する調査研究 平成21年度総括・分担研究報告書 (班長坪内博仁), 2009, 34-40
 
P.269 掲載の参考文献
1) 森俊幸, 佐田尚宏, 梛野正人他 : 肝内結石症全国疫学調査. 肝内結石症に関する調査研究, 平成17-19年度 総合研究報告書, 2008
 
2) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 (編) : 肝内結石症の診療ガイド, 文光堂, 2011
 
3) 佐田尚宏, 小泉大, 安田是和他 : 肝内結石症の新しい画像診断指針. 胆と膵 28 ; 501-504, 2007
Medical*Online
4) Park HS, Lee JM, Kim SH, et al. : CT Differentiation of cholangiocarcinoma from periductal fibrosis in patients with hepatolithiasis. Am J Roentgenol 187 ; 445-453, 2006
 
P.273 掲載の参考文献
1) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 (編) : 肝内結石症の診療ガイド, 文光堂, 2011
 
2) Nakanuma Y, Sasaki M, Sato Y, et al. : Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World J Hepatol 1 ; 35-42, 2009
PubMed
3) Bosman FT, Carneiro F, Hruban RH, et al., eds. : WHO Classification of Tumors of the Digestive System, 4th ed., IARC Press, 2010
 
4) Zen Y, Adsay NV, Bardadin K, et al. : Biliary intraepithelial neoplasia : an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20 ; 701-709, 2007
PubMed
5) Chen TC, Nakanuma Y, Zen Y, et al. : Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 34 ; 651-658, 2001
PubMed
6) Zen Y, Fujii T, Itatsu K, et al. : Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44 ; 1333-1343, 2006
PubMed
7) Kloppel G, Adsay V, Konukiewitz B, et al. : Precancerous lesions of the biliary tree. Best Pract Res Clin Gastroenterol 27 ; 285-297, 2013
PubMed
8) Zen Y, Sasaki M, Fujii T, et al. : Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 44 ; 350-358, 2006
PubMed
9) Sato Y, Sasaki M, Harada K, et al. : Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia. J Gastroenterol 49 ; 64-72, 2014
PubMed
10) Kubota K, Nakanuma Y, Kondo F, et al. : Clinicopathological features and prognosis of mucin-producing bile duct tumor and mucinous cystic tumor of the liver : a multi-institutional study by the Japan Biliary Association. J Hepatobiliary Pancreat Sci 21 ; 176-185, 2014
PubMed
P.278 掲載の参考文献
1) Suzuki Y, Mori T, Abe N, et al. : Predictive factors for cholangiocarcinoma associated with hepatolithiasis determined on the basis of Japanese Multicenter study. Hepatol Res 42 ; 166-170, 2012
PubMed
2) Tabrizian P, Jibara G, Shrager B, et al. : Hepatic resection for primary hepatolithiasis : a single-center Western experience. J Am Coll Surg 215 ; 622-626, 2012
PubMed
3) 古川正人, 佐々木誠, 大坪光次他 : 肝内結石症例の自然経過. 胆と膵 19 ; 1021-1027, 1998
Medical*Online
4) 岡田周市, 木村邦夫, 税所宏光他 : 肝内型ならびに肝内優位型肝内胆石症の非手術例における長期遠隔成績. 日消誌 87 ; 218-224, 1990
 
5) 土屋慎, 露口利夫, 酒井裕司他 : 当院における末梢型肝内結石の診療-無症状症例の取り扱い-. 胆と膵 28 ; 505-508, 2007
Medical*Online
6) 正田純一, 田中直見, 跡見裕 : 肝内結石の変遷ならびに内科的処置. 肝胆膵 52 ; 773-782, 2006
Medical*Online
7) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会 (編) : 急性胆管炎・胆嚢炎診療ガイドライン 2013, 医学図書出版, 2013
 
8) Tsui WM, Chan YK, Wong CT, et al. : Hepatolithiasis and the syndrome of recurrent pyogenic cholangitis : clinical, radiologic, and pathologic features. Semin Liver Dis 31 ; 33-48, 2011
PubMed
9) Okugawa T, Tsuyuguchi T, K C S, et al. : Peroral cholangioscopic treatment of hepatolithiasis : Longterm results. Gastrointest Endosc 56 ; 366-371, 2002
PubMed
10) Shimatani M, Matsushita M, Takaoka M, et al. : Effective "short" double-balloon enteroscope for diagnostic and therapeutic ERCP in patients with altered gastrointestinal anatomy : a large case series. Surg Laparosc Endosc 41 ; 849-854, 2009
 
P.285 掲載の参考文献
1) Uchiyama K, Onishi H, Tani M, et al. : Indication and procedure for treatment of hepatolithiasis. Arch Surg 137 ; 149-153, 2002
PubMed
2) Tian J, Li JW, Chen J, et al. : The safety and feasibility of reoperation for the treatment of hepatolithiasis by laparoscopic approach. Surg Endosc 27 ; 1315-1320, 2013
PubMed
3) 田妻進 : 肝内結石症全国疫学調査. 厚生労働科学研究費補助金 難治性疾患克服研究事業 平成24年度肝内結石症に関する調査研究報告書, 2013, p 161-163
 
4) 森俊幸, 佐田尚宏, 梛野正人他 : 肝内結石症全国疫学調査. 厚生労働科学研究費補助金 難治性疾患克服研究事業 平成20年度肝内結石症に関する調査研究報告書, 2007, p 22-25
 
5) 谷村弘, 内山和久, 石本喜和男 : 肝内結石症の全国疫学調査. 厚生省特定疾患肝内結石症調査研究班報告書, 1996, p 11-19
 
6) Uchiyama K, Kawai M, Ueno M, et al. : Reducing residual and recurrent stones by hepatectomy for hepatolithiasis. J Gastrointest Surg 11 ; 626-630, 2007
PubMed
7) Uchiyama K, Ueno M, Ozawa S, et al. : Combined intraoperative use of contrast-enhanced ultrasonography imaging using a sonazoid and fluorescence navigation system with indocyanine green during anatomical hepatectomy. Langenbecks Arch Surg 396 ; 1101-1107, 2011
PubMed
8) Uchiyama K, Ueno M, Ozawa S, et al. : Risk factors for postoperative infectious complications after hepatectomy. J Hepatobiliary Pancreat Sci 18 ; 67-73, 2011
PubMed
9) Tu JF, Jiang FZ, Zhu HL, et al. : Laparoscopic vs open left hepatectomy for hepatolithiasis. World J Gastroenterol 16 ; 2818-2823, 2010
PubMed
P.288 掲載の参考文献
1) Shaib Y, El-Seraq HB : The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 ; 115-125, 2004
 
2) Kawamoto T, Shoda J, Irimura T, et al. : Expression of MUC1 mucins in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res 7 ; 1333-1342, 2001
PubMed
3) Miyahara N, Shoda J, Kawamoto T, et al. : Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res 10 ; 2090-2099, 2004
 
4) Kuno A, Uchiyama N, Koseki-Kuno S, et al. : Evanescent-field fluorescence-assisted lectin microarray : a new strategy for glycan profiling. Nat Methods 2 ; 851-856, 2005
PubMed
5) Onuki K, Sugiyama H, Ishige K, et al. : Expression of N-acetylglucosaminyltransferase V in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. J Gastroenterol, 2013 [in press]
 
6) Matsuda A, Kuno A, Kawamoto T, et al. : Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology 52 ; 174-182, 2010
PubMed
P.297 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等克服研究事業・門脈血行異常に関する調査研究班 : 特発性門脈圧亢進症診断のガイドライン. 平成24年度研究報告書, 2013
 
2) 佐藤武彦, 佐藤孝, 笹生俊一他 : 特発性門脈圧亢進症における脾臓の病理. 肝胆膵 22 ; 619-626, 1991
 
3) 塩見進, 黒木哲夫 : 特発性門脈圧亢進症. 肝胆膵 38 ; 51-55, 1999
 
4) Schouten JN, Garcia-Pagen JC, Janssen HL : Idiopatic non-cirrhotic portal hypertension. Hepatology 54 ; 1071-1081, 2011
 
5) Kransinskas AM : Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 11 ; 627-634, 2005
 
6) 小林聡, 松井修, 蒲田敏文他 : 門脈圧血行異常症の画像診断update. 肝胆膵 61 ; 181-189, 2010
 
7) 日本門脈圧亢進症学会 (編) : 特発性門脈圧亢進症idiopathic portal hypertension. 門脈圧亢進症取扱い規約, 金原出版, 2013
 
8) Furuichi Y, Moriyasu F, Taira J, et al. : Noninvasive diagnostic method for idiopathic portal hypertension based on measurements of liver and spleen stiffness by ARFI elastography. J Gastroenterol 48 ; 1061-1068, 2013
PubMed
P.301 掲載の参考文献
1) 日本門脈圧亢進症学会 (編) : 門脈圧亢進症取り扱い規約 第3版, 金原出版, 2013
 
2) 杉浦光雄 : 病因と症状. 現代外科学体系 (40A) 門脈・副腎, 中山書店, 1970, p 35-140
 
P.304 掲載の参考文献
1) DeLeve LD, Valla DC, Garcia-Tsao G, et al. : Vascular disorders of the liver. Hepatology 49 ; 1729-1764, 2009
PubMed
2) 吉本次郎, 川崎誠治 : 門脈血栓症. 外科 67 ; 1069-1076, 2005
 
3) Tsochatzis EA, Senzolo M, Germani G, et al. : Systematic review : portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 31 ; 366-374, 2010
PubMed
4) Huard G, Bilodeau M : Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis : a systematic review. Int J Hepatol 2012 ; 672986, 2012
PubMed
P.307 掲載の参考文献
1) 日本門脈圧亢進症食道静脈瘤学会 (編) : VI 病理. 門脈圧亢進症取扱い規約, 金原出版, 2013, p 73
 
2) Shulman HM, Fisher LB, Schoch HG, et al. : Venoocclusive disease of the liver after marrow transplantation : histological correlates of clinical signs and symptoms. Hepatology 19 ; 1171-1181, 1994
 
3) DeLeve LD, Shulman HM, McDonald GB : Characterization of a reproducible rat model of hepatic venoocclusive disease. Hepatology 29 ; 1779-1791, 1999
 
4) McDonald GB, Hinds MS, Fisher LD, et al. : Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients. Ann Intern Med 118 ; 255-267, 1993
PubMed
5) McDonald GB, Sharma P, Matthews D, et al. : Venocclusive disease of the liver after bone marrow transplantation : diagnosis, incidence, and predisposing factors. Hepatology 4 ; 116-122, 1984
PubMed
6) Carreras E, Bertz H, Arcese W, et al. : Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation : a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92 ; 3599-3604, 1998
PubMed
7) Hasegawa S, Horibe K, Kawabe T, et al. : Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies : incidence, onset time and risk factors. Bone Marrow Transplant 22 ; 1191-1197, 1998
PubMed
8) Shulman HM, Gown AM, Nugent, DJ : Hepatic venoocclusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 127 ; 549-558, 1987
PubMed
P.312 掲載の参考文献
1) 村島直哉, 國分茂博, 近森文夫 : 門脈血行動態の画像診断 1.3D-CTによる診断. [改訂第3版] 食道・胃静脈瘤, 日本メディカルセンター, 2012, 123-131
 
2) 村上匡人, 國分茂博 : 食道胃静脈瘤血行動態における左胃動脈造影 (LGA) の有用性-内視鏡的静脈瘤造影 (EVIS) との対比から. 肝臓 34 ; 965-974, 1993
 
3) 中村真一, 村田洋子, 今井隆二郎 他 : EUSからみた食道静脈瘤の診断と治療. 臨床消化器内科 20 ; 519-526, 2007
 
4) Hidaka H, Wang G, Nakazawa T, et al. : Total and viable residual splenic volume measurement after partial splenic embolization by three-dimensional ultrasound. J Med Ultrasonics 40 ; 417-424, 2013
 
5) 中村真一他 : 食道動脈瘤治療におけるEVL, EISの位置付け. Modern Physician 26 ; 1069-1077, 2006
 
P.317 掲載の参考文献
1) 冲永功太 : 肝硬変症による門脈圧亢進症. 脾臓-基礎と臨床-, へるす出版, 2011, p 169-177
 
2) Maddison FE : Embolic therapy of hypersplenism. Invest Radiol 8 ; 280-281, 1973
 
3) Spigos DG, Jonasson O, Mozes M, et al. : Partial splenic embolization in the treatment of hypersplenism. AJR 132 ; 777-782, 1979
PubMed
4) Shimizu H, Takatsuka K, Yoshida A, et al. : Partial splenic embolization reverses insulin resistance in patients with liver cirrhosis. Inter Med 48 ; 747-751, 2009
 
5) 田尻孝 : 脾機能亢進症に対する脾動脈塞栓療法. 肝臓病学の進歩 18 ; 51-60, 1992
 
6) Sherlock S, Dooley J : Disease of the Liver and Biliary system (11th ed.), Blackwell Publishing and Science, 2002, p 170
 
7) Kanagawa H, Mima S, Kouyama H, et al. : Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 11 ; 51-58, 1996
PubMed
8) 村島直哉, 國分茂博, 近森文夫 : 孤立性胃静脈瘤治療. [改訂第3版] 食道・胃静脈瘤, 日本メディカルセンター, 2012, p 256
 
P.322 掲載の参考文献
1) 赤星朋比古, 富川盛雅, 川中博文 他 : 門脈圧亢進症患者に対する腹腔鏡下脾臓摘出術. 日本門脈圧亢進症学会雑誌 17 ; 56-62, 2011
 
2) Hassab MA : Gastroesophageal decongestion and splenectomy in the treatment of esophageal varices in bilharzial cirrhosis : further studies with a report on 355 operations. Surgery 61 ; 169-176, 1967
PubMed
3) 赤星朋比古, 橋爪誠 : 孤立性胃静脈瘤に対する腹腔鏡下治療. [改訂版第3版] 食道・胃静脈瘤, 日本メディカルセンター, 2012, 260-264
 
P.325 掲載の参考文献
1) Petruff CA, Chopra S : Classification of portal hypertension. Handbook of liver disease, Churchill Livingstone, 2004, pp 264-265
 
2) Rappaport AM : The microcirculatory hepatic unit. Macrovas Res 6 ; 212-228, 1973
 
3) 織田正也 : 肝類洞内皮細胞の超微形態と機能. 肝臓 25 ; 1639-1643, 1984
 
4) Thabut D, Shah V : Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease : new targets for the treatment of portal hypertension? J Hepatol 53 ; 976-980, 2010
PubMed
5) Sakamoto M, Ueno T, Kin M, et al. : Ito cell contraction in response to endothelin- 1 and substance P. Hepatology 18 ; 978-983, 1993
PubMed
6) Garcia-Criado FJ, Toledo-Pereyra LH, Lopez-Neblina F, et al. : Role of P-selectin in total hepatic ischemia and reperfusion. J Am Coll Surg 181 ; 327-334, 1995
PubMed
7) Reiberger T, Angermayr B, Schwabl P, et al. : Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 51 ; 865-873, 2009
PubMed
8) Wang Y, Gao J, Zhang D, et al. : New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 53 ; 132-144, 2010
 
9) Pinter M, Sieghart W, Reiberger T, et al. : The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. Aliment Pharmacol Ther 35 ; 83-91, 2012
PubMed
P.330 掲載の参考文献
1) Sohda T, Okubo R, Kamimura S, et al. : Hemochromatosis with HFE gene mutation in a Japanese patient. Am J Gastroenterol 96 ; 2487-2488, 2001
 
2) Maeda T, Nakamaki T, Saito B, et al. : Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox : improvement of liver disease activity, cardiac and hematological function. Eur J Heamatol 87 ; 467-469, 2011
 
3) Hattori A, Tomosugi N, Tatsumi Y, et al. : Identification of a novel mutation in the HAMP gene that causes non-detectable hepcidin molecule in a Japanese male patient with juvenile hemochromatosis. Blood Cells Mol Dis 48 ; 179-182, 2012
 
4) Takatoku M, Uchiyama T, Okamoto S, et al. : Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 78 ; 487-494, 2007
PubMed
5) Olivieri NF, Nathan DG, MacMillan JH, et al. : Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331 ; 574-578, 1994
PubMed
P.334 掲載の参考文献
1) Roberts EA, Schilsky ML : Diagnosis and treatment of Wilson disease : an update. Hepatology 47 ; 2089-2111, 2008
PubMed
2) European Association for the Study of the Liver : EASL clinical practice guidelines : Wilson's desease. J Hepatol 56 ; 671-685, 2012
 
3) Harada M : Wilson disease. Med Electron Microsc 35 ; 61-66, 2002
PubMed
4) Harada M, Sakisaka S, Terada K, et al. : Role of ATP7B in biliary copper excretion in a human hepatoma cell line and normal rat hepatocytes. Gastroenterology 118 ; 921-928, 2000
 
5) Harada M, Sakisaka S, Terada K, et al. : A mutation of the Wilson disease protein, ATP 7 B, is degraded in the proteasomes and forms protein aggregates. Gastroenterology 120 ; 967-974, 2001
 
6) Terada K, Nakako T, Yang XL, et al. : Restoration of holoceruloplasmin synthesis in LEC rat after infusion of recombinant adeno virus bearing WND cDNA. J Biol Chem 273 ; 1815-1820, 1998
 
7) Yanagimoto C, Harada M, Kumemura H, et al. : Niemann-Pick C1 protein transports copper to the secretory compartment from late endosomes where ATP7B resides. Exp Cell Res 315 ; 119-126, 2009
 
8) Weiss KH, Thurik F, Gotthardt DN, et al. : Efficacy and Safety of Oral Chelators in Treatment of Patients with Wilson Disease. Clin Gastroenterol Hepatol 11 ; 1028-1035, 2013
PubMed
9) Weiss KH, Gotthardt DN, Klemm D, et al. : Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 140 ; 1189-1198, 2011
 
10) Akyildiz BZ, Yidirim S, Kondolot M, et al. : Is plasma exchange effective in prevention of hepatic transplantation in fulminant Wilson disease with hepatic failure? J Pediatr Gastroenterol Nutr 52 ; 778-780, 2011
 

書評

最近チェックした商品履歴

Loading...